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MODULATION OF THE RECEPTOR GATING MECHANISM AND ALLOSTERIC
COMMUNICATION IN IONOTROPIC GLUTAMATE RECEPTORS

Nabina Paudyal, M.S.

Advisory Professor: Vasanthi Jayaraman, Ph.D.

ABSTRACT

Ionotropic glutamate receptors (iGluRs) found in mammalian brain are primarily known to
mediate excitatory synaptic transmission crucial for learning and memory formation. The
family of iGluRs consists of AMPA receptors, NMDA receptors and kainate receptors with
each member having distinct physiological role. In the recent years, significant progress has
been made in understanding the biophysical, and functional properties of iGluRs. The
development of Cryo-EM and X-Ray crystallography techniques have further facilitated in
the structural understanding of these receptors. However, the multidomain nature, large
size of the protein, complex gating mechanism and inadequate knowledge regarding the
conformational dynamics of the receptors during channel gating mechanism have been
some of the limiting factors in elucidating the structure-function relation of iGluRs. Thus,
to understand the conformational dynamics of iGluR family and correlate to its functional
behavior, I have utilized single molecule Forster Resonance Energy Transfer (smFRET) and
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molecular dynamics simulation and specifically investigated the factors influencing gating
mechanism and allosteric communication in heteromeric kainate receptor GluK2/K5 and
NMDA receptor GluN1/N2A. Some of the major finding in this dissertation includes subunit
arrangement of GluK2/K5 and its dynamics involved in resting and desensitized conditions.
For the first time we have identified the conformational changes induced at GluK2 and
GluK5 subunits in a heteromer GluK2/K5 when bound to different agonists. Utilizing MD
simulations in GluN1/N2A NMDA receptors we have identified the structural pathway
regarding the mechanism underlying negative cooperativity and how mutation in the
receptor leads to abnormal functional behavior. These findings will allow us to understand
the conformational control regarding modulation of receptor function and will serve as a
basis for developing subunit and conformation-specific therapeutic drugs that can
potentially control the abnormal activity of the receptors linked to several neurological
diseases
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INTRODUCTION

1.1

Synaptic transmission in the human brain

The mammalian brain consists of a large network of neuronal circuits where each
neuron behaves as a signaling unit (1). The information is relayed between neurons through
a specialized junction called a synapse (electrical or chemical). Electrical synapses are
physically connected through gap junction channels (2). In the chemical synapse, the
connection between neurons involves the release of chemical substances called
neurotransmitters that bind to proteins and open transmembrane ion channels (1, 3). Ions
move across the membrane down the electrochemical gradient leading to a change in the
membrane potential. The change in membrane potential plays a major role in neuronal
signaling (3).

The electrochemical gradient across the membrane is set up by the asymmetric
distribution of ions (Na+, K+, Cl-) across the membrane in neurons which generate a resting
membrane potential of -70 mV. When the membrane potential is more negative than
resting potential due to inhibitory signaling, the membrane is hyperpolarized (3). An
example of such signaling is movement of chloride ions into the cell through anion selective
channels such as the ionotropic gamma amino butyric acid (GABA) receptors. When the
membrane potential is more positive than resting potential due to excitatory signaling it
results in membrane depolarization (3). An example of such signaling is movement of
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sodium ions into the cell through cation specific channels such as the ionotropic glutamate
receptors (iGluRs).

Depolarization of the receiving neuron beyond a certain threshold potential value opens
voltage gated channels, that amplify the signal leading to generation of an action potential.
Action potentials, in turn, result in the transfer of signal from one neuron to another neuron
(3). In the chemical synapse the action potential leads to neurotransmitters being released
in the synapse. Depending on the type of neurotransmitters released and receptors
activated at post-synaptic neurons, the post-synaptic potential might be excitatory or
inhibitory, thus leading to continued signaling across neurons.

In the post-synaptic region, there are ionotropic receptors and metabotropic receptors
that activate during synaptic transmission (1, 3). The synaptic transmission induced due to
ionotropic receptors is fast and brief because the ion channels activate directly by
conformational rearrangement of the receptor. Whereas, metabotropic receptors trigger
biochemical signaling pathways for synaptic transmission. This process is slow and persists
for a long period of time. During the gating mechanism in metabotropic receptors, ion
conduction is not achieved through direct conformational changes but rather involves the
activation of signaling cascades (1, 3).

In mammalian brain, neurotransmitters such as glutamate activate excitatory
neurotransmitter receptors. The iGluRs are regarded as the key mediators of excitatory
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synaptic transmission (4). This dissertation is mainly focused on understanding the
structure-function relation in iGluRs that occurs during synaptic transmission.

1.2

Ionotropic glutamate receptors (iGluRs)

The iGluRs are cation-selective ligand-gated ion channels and are regarded as the
predominant excitatory neurotransmitter receptors in the central nervous system.
Glutamate binds to these iGluRs inducing conformational change for activating these
receptors, and mediating fast excitatory synaptic transmission. Thus, these iGluRs are
involved in a number of important processes such as cognition, learning and memory
formation (4-9).

The cloning of the first iGluR gene was reported in 1989 (10). Later, other iGluR genes
were also identified, followed by the standard nomenclature of iGluR subtypes (11). Based
on their pharmacological profile and sequence homology, the members of iGluRs are
grouped as NMDA (N-methyl-D-aspartic acid) receptors, AMPA (α-amino-3-hydroxy-5methyl-4-isoxazole propionic acid) receptors, and kainate receptors. The subtypes of iGluR
family are shown in Figure 1-1.

The iGluRs function as tetrameric proteins. AMPA and kainate receptors are named
after their selective activation to the synthetic agonists AMPA and kainate, respectively.
Both AMPA and kainate receptors can form functional homomers or heteromers from their
respective subunit subtypes and activate upon glutamate binding. These receptors are
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permeable to Na+ and K+ ions and are weakly permeable to Ca++ ions. AMPA receptors
demonstrate faster gating kinetics in mediating post-synaptic current as compared to
kainate receptors (4, 5). AMPA receptors are ubiquitously expressed in the brain and are
found to be important for basal excitatory synaptic transmission (4, 5). Kainate receptors
similar to AMPA and NMDA receptors are found both in the pre-synaptic and post-synaptic
region. In comparison to AMPA and NMDA receptors, kainate receptors are generally
known to participate in neuronal modulation, and control neurotransmitter release in
addition to mediating excitatory post-synaptic current (8).

Figure 1-1. Subunit subtypes of ionotropic glutamate receptors

NMDA receptors are named after their selective activation to the agonist NMDA. These
receptors are obligate heteromers which assemble from two or more different subunits for
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the formation of a functional tetramer. These receptors are unique amongst other members
of iGluR family because they require simultaneous binding of both glutamate and glycine
for receptor activation (4, 12). In addition, the presence of Mg++ ion at the receptor pore
blocks the channel permeability at the resting membrane potential, allowing only for the
passing of ions during membrane depolarization (13). Membrane depolarization could occur
due to the activation of AMPA and kainate receptors triggering the activation of NMDA
receptors. Thus, NMDA receptors are also known as coincidence detectors (4, 5). In addition
to Na+ and K+ ions, NMDA receptors are also responsible for the large influx of Ca++ ions in
the postsynaptic region (6). In comparison to AMPA and kainate receptors, NMDA
receptors contribute to the slow gating kinetics and extended phase of excitatory post
synaptic current important for long term potentiation involved in synaptic plasticity (14, 15).

Over the last two decades remarkable efforts have been made to understand the
molecular mechanism of iGluRs involved in synaptic plasticity. The cloning of iGluR genes
has not only facilitated in understanding their distinct physiological roles, but also aided in
solving crystal structures, enabling us to understand the structure-function relation of the
receptor. This has opened avenues for structure-based drug design and for developing
potential therapeutics for CNS disorders (5). However, understanding the complete
mechanism of these receptors is still a challenge due to several reasons such as- a) the
diversified population of iGluRs subtype having unique functional properties, b) the
probability of forming isoforms modulating the channel properties, c) the difference in the
expression level of the various iGluR subtypes and d) the possibility of off-target effects due
to orthosteric ligands because of the conserved glutamate binding sites in iGluRs (5, 16) .
5

There are several drug molecules such as NMDA receptor-specific allosteric modulators,
antagonists, and AMPA receptor antagonists that have paved the way for clinical trials in
recent years. Yet, they have been discontinued due to their inefficacy, poor pharmacokinetic
profile, and off-target effects (16). One way in which the above limitations can be addressed
is by studying protein dynamics and understanding the conformational changes induced in
the receptor under different conditions (17). This will provide a platform for developing
subunit and conformation-specific therapeutic drugs that can potentially reduce the abovementioned challenges, and control the abnormal activity of the receptors linked to several
neurological diseases.

1.3

Structural insight of iGluRs

The implication of iGluRs in several neurological disorders has largely motivated the
understanding of the structure-function relationship in the iGluR family. With the use of
biophysical techniques such as single particle Cryo-EM (electron microscopy) and X-ray
crystallography, several isolated domains as well as full-length structures of the iGluR family
have been solved (18-28). Based on their sequence homology and their membrane-spanning
structures, iGluRs are known to share a similar architecture (4, 18, 29). These receptors are
tetrameric multidomain proteins. The subunits are arranged as dimers of dimers with a
domain swapping configuration in the extracellular region (Figure 1-2) (4, 18, 29). The
functional receptor is only formed by the assembly of subunits from the same class of iGluR
family. Each subunit in a receptor consists of an extracellular amino-terminal domain
(ATD), an extracellular agonist-binding domain (ABD), a transmembrane domain (TMD),
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and an intracellular carboxy-terminal domain (CTD) (4, 18, 29). Each domain within a
subunit is connected to the next domain by a polypeptide stretch known as a linker. The
conformational changes induced in one domain are communicated to the other domain
with the help of these linkers. The role of each domain in a receptor is discussed in detail
below.
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Figure 1-2. Structural topology of ionotropic glutamate receptors (iGluRs).
Panel A: Schematic representation of iGluR subunit consisting of clamshell-like
extracellular amino terminal domain (ATD) and agonist binding domain (ABD),
transmembrane domain (TMD) and intracellular c-terminal domain (CTD). Panel B-D:
Side view of the structures of AMPA receptor (PBD: 3KG2) in panel B, NMDA receptor
(PBD: 4PE5) in panel C and Kainate receptor (PBD: 7KS0) in panel D showing similar
architecture. The spheres in panel B represent the top-down view of the subunits in
tetrameric arrangement (chain A in pink, chain B in blue, chain C in green, and chain D
in yellow) showing domain swapping arrangements between ATD and ABD.
8

1.3.1

The Carboxy-Terminal Domain

The intracellular C-terminal domain (CTD) of iGluR family has the most diversified
domain length and amino acid sequence (sequence identity: ~60% between AMPA
receptors subunits, ~13% between kainate receptor subunits and only ~3% between NMDA
receptor subunits) (4). This domain is considered to have highly disordered regions; as such
the crystal structure of the CTD has not been solved yet. Only except a small region in the
NDMA receptor which is responsible for binding calcium-calmodulin (Ca++/CaM) has been
solved (30). The intracellular CTD of iGluRs is known to participate in several processes
such as protein-protein interaction, post-translational modification, membrane targeting,
receptor stabilization and receptor degradation (4). For instance, a number of sites
identified in AMPA receptor CTD for phosphorylation mediate protein-protein interaction,
which facilitates receptor trafficking, and in some cases controls subunit dependent
receptor function by increasing the open probability of the receptor (4). Similarly, the
phosphorylation at the CTD in kainate receptors is also known to regulate protein-protein
interaction, protein trafficking and potentiate receptor activation (4). The phosphorylation
at the CTD of NMDA receptors regulates calcium-ion dependent desensitization in addition
to controlling receptor trafficking and protein-protein interaction (4). Besides
phosphorylation, iGluRs can also undergo palmitoylation impacting receptor localization,
(31) and SUMOylation mediating receptor endocytosis (32). The CTD of some subtypes of
iGluRs can undergo alternative splicing and could alter the CTD sequence creating
functionally distinct iGluRs (4). Altogether, the above-mentioned processes play a critical
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role in regulating synaptic plasticity. Of all the domains of iGluRs, the CTD has been the
least studied and more detailed investigations need to be done to understand its function.

1.3.2

The Amino-Terminal Domain

AMPA

NMDA

Kainate

R1

R1

R1

R2

R2

R2

Figure 1-3. Side view of ATD dimer structure of AMPA receptor (green), NMDA receptor
(blue) and kainate receptor (orange).
The structures represent the interactions between R1-R1 and R2-R2 lobes between
subunits in iGluRs. AMPA receptor (PDB: 3KG2) and kainate receptor (PDB: 7KS0) show
extensive interaction between R1-R1 and R2-R2 lobes and smaller angle between R1 and
R2 lobes. NMDA receptor (PDB: 4PE5) show only interaction with R1-R1 lobes between
subunits and also larger angle between R1 and R2 lobes in ATD.

The extracellular amino-terminal domain (ATD) consists of about 400-450 amino
acid residues and starts after the 14- to 33-residue signal peptide sequence in a functional
receptor (4). The ATD is the largest domain in a receptor subunit and is also the most
evolutionarily diverse region (4). Receptor assembly begins with the subunit dimerization
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at the ATD, and this subsequently leads to the specified dimer of dimer arrangement.
Depending on the affinities for subunit interactions, the ATD favors the formation and
trafficking of stable homomeric or heteromeric complexes (29, 33). The ATD structures
(isolated or in a full-length receptor) are bi-lobed in nature consisting of an upper lobe as a
regulatory domain R1 and a lower lobe as regulatory domain R2 as shown in Figure 1-2 (4,
18, 29). In AMPA and kainate receptors, the relative orientation of each lobe varies by up to
10° while that in NMDA receptor varies by up to 50° (4, 18, 29, 33). This difference in the
domain movement is due to the extensive interaction between ATD subunits forming
contacts and is shown in Figure 1-3 (4, 18, 29, 33). The ATD of iGluRs harbors sites for
binding with extracellular proteins, auxiliary proteins, interacting proteins and receptor
glycosylation that can influence ligand affinities, receptor trafficking and receptor function
(4, 18, 29, 33). Additionally, the NMDA receptor ATD possesses binding sites for allosteric
modulators, such as ifenprodil, as well as ions like Zn2+ that can modulate the function of
the receptor by influencing the open probability of the channel, deactivation kinetics, and
allosteric regulation (4). In the case of AMPARs and KARs, no such modulators or ions are
known to bind the ATD site and hence, the major role of ATD in AMPA and kainate
receptors have been considered to participate in subunit arrangement and assembly (4).
Although the ATD directs subunit assembly, the deletion of the ATD in iGluRs have shown
that iGluRs can still form functional tetramers, suggesting that the ATDs are not completely
essential for receptor assembly (4). The exact mechanism of the ATD in regulating ion
channel function still requires further investigations.
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1.3.3

The Agonist-Binding Domain

The agonist-binding domain (ABD) resides at the extracellular region following the
ATD and forms the most conserved domain in the iGluR family (sequence identity: ~100%
between subunits in AMPA receptors, ~92% between subunits in kainate receptors and
~70% between subunits in NMDA receptors) (4). This domain includes two polypeptide
stretches—S1 and S2 (34). S1 mostly forms the first half of the ABD lobe D1 connected to the
transmembrane helix M1, and S2 mostly forms the second half of the ABD lobe D2
connected to the transmembrane helices M3 and M4 (18). The lobes D1 and D2 are arranged
to form a bi-lobed clamshell-like structure constituting a cleft (Figure 1-2). There are
residues within the cleft region that are identified as sites involved in the binding of ligands
(Figure 1-4) (18). When an agonist such as glutamate binds to the cleft, the domain closes.
With this domain closure, the strain is produced in the linker connecting S2 and M3. This
linker is predicted to play an important role in channel gating. The conformational change
induced in the ABD causing cleft closure produces strain in this linker which is then
communicated to the transmembrane domains for channel gating (18).

Similar to the ATD, the subunits in the ABD are also arranged as dimers of dimers
but the partnered protomers are swapped between subunits (Figure 1-2) (4, 18, 29). When
the agonist is bound to the cleft for a long period of time, then the distance between D1-D1
lobes of two subunits forming dimer interface is observed to increase leading to dimer
decoupling as shown in Figure 1-4 (18-24, 27, 28, 35). The ABD dimer decoupling in iGluRs
is thought to drive the process of receptor desensitization (4, 18, 29). During receptor
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desensitization, the channel returns to a non-conductive state. In kainate receptors,
external ions Na+ and Cl- are present at the dimer interface that are crucial for receptor
activation and are predicted to increase the stability of the dimer interface (33). During
receptor desensitization, the ions are unbound, and the dimer interface disrupts. The extent
of dimer decoupling during receptor desensitization is larger in kainate receptors than
AMPA and NMDA receptors and is thought to be a unique feature of kainate receptors (29,
33). In AMPA receptors, three classes of desensitized states of the receptors are identified
with each class showing different extent of dimer decoupling (21). In a crosslinking
experiment, it has been shown that the dimer decoupling in AMPA is not essential for
driving receptor desensitization (36). In kainate receptor GluK2, the mutation D776K has
stabilized the dimer interface by maintaining the closer distance between D1-D1 lobe at the
interface and has changed the receptor to a non-desensitizing state (37). However, the
requirement of dimer decoupling leading to receptor desensitization in the kainate receptor
is not fully understood yet. In Chapter 4 the receptor desensitization mechanism in
heteromer GluK2/K5 kainate receptor subtype is discussed.
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Figure 1-4. ABD structure and arrangement.
Panel A: Cartoon representation showing side view of a bi-lobed (D1 and D2) isolated
agonist binding domain (ABD) with glutamate (blue) bound to the cleft. Stars represent
the site at the polypeptide stretches S1 and S2 that are connected to transmembrane
helices (M1, M3 and M4) through linkers (not shown). Panel B-C: Top-down view of an
ABD of a kainate receptor tetramer in antagonist bound form (PDB: 5KUF) with intact
dimer interface represented by shorter distance between D1-D1 distances of subunits
(represented in double arrow dotted line) in panel B and larger distance between subunits
representing dimer decoupling in glutamate bound desensitized (PDB: 5KUH) state in
panel C. Four subunits in a receptor are represented as chain A in pink, chain B in blue,
chain C in green, and chain D in yellow.
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In NMDA receptors, both glutamate and glycine are required for receptor activation.
From sequence alignment it has been known that in NMDA receptors, the residues in GluN2
subunits that bind to glutamate are conserved. Similarly, the residues involved in binding
glycine in GluN1 and GluN3 subunits are conserved (4). Functional studies have shown that
a negative cooperativity mechanism between glutamate and glycine reduces their binding
affinity (38). In addition, a mutation has been reported in GluN1 of NMDA receptor, which
has shown a decrease in glutamate potency and increased deactivation response (39). In
Chapter 6, the structural mechanism underlying negative cooperativity and the mechanism
of how mutations in the glycine-binding domain have influenced the functional properties
of the NMDA receptor has been further discussed.

In the AMPA receptor family, the residues involved in binding the agonist for
inducing conformational changes are found to be conserved (4). The residues in the kainate
receptors family that participate in the binding of agonists are not fully conserved (4). This
correlates with functional studies which have shown that molecules behaving as partial
agonists in some kainate receptor subtypes do not induce a current in other subtypes. This
fact can be implemented in developing subunit-specific therapeutic drugs in kainate
receptors. Also, crystal structures and Cryo-EM structures of AMPA and homomeric
subtype of kainate receptors complexed to different agonists have shown different degrees
of cleft closure (33, 40-47). The cross-linking studies (48), NMR (Nuclear Magnetic
Resonance) studies (49, 50), and FRET investigations (51-54) have demonstrated detailed
mechanisms underlying partial agonism in AMPA receptors, whereas that for kainate
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receptors is still limited. In Chapter 5, the partial agonism mechanism in a full-length
heteromeric kainate receptor (GluK2/K5) has been discussed.

1.3.4

The Transmembrane Domain

Figure 1-5. Structure of the TMD representing iGluR pore.
Panel A: Top-down view of the transmembrane segments arranging to form a channel
pore with helix M3 forming the core of the ion channel. Panel B: Side view of the TMD
segments representing M2 forming the inner lining of the pore. Four subunits in a
receptor are represented as chain A in pink, chain B in blue, chain C in green, and chain
D in yellow.

The transmembrane segments of iGluRs form the core of the ion channel. Each
subunit in a receptor consists of three transmembrane helices called M1, M3, M4, one reentrant loop called M2, and a small portion of M1 helix which orients parallel to the plane
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of the membrane called the pre-M1 helix (4, 18). The TMD assemble similar to the inverted
structure of potassium channels with pseudo-four-fold symmetry (55). At the pore cavity,
M2 forms the inner lining with narrow constriction, and M3 forms the outer lining and
controls the permeation of the cations (18). The M2 re-entrant loop in TMD consists of
Q/R/N site where glutamine (Q) is edited to arginine (R) post-transcriptionally altering the
permeation property of the channel (18). AMPA and kainate receptors with unedited forms
display higher calcium permeability than compared to edited forms (56, 57). Majority of the
AMPA receptors found have edited forms while that for kainate receptors remains unclear
(8, 58). In the closed channel state, the apex of the M3 helices is tightly crossed blocking the
channel pore (18). This region of M3 forms the extracellular part of the pore region
consisting of a highly conserved SYTANLAAF motif and is crucial for the normal channel
gating mechanism (18). Mutation in this region has changed the receptor to a constitutively
active form, and has slowed channel kinetics by decreasing the rate of deactivation and
desensitization in the receptor (59, 60). Helices M1 and M4 are located at the exterior region
of M3 helices (18). In AMPA receptors, the elimination of the M4 helix has been shown to
alter receptor trafficking (61). While the actual role of these segments in channel gating is
still unclear, it is thought that these segments contribute to channel stability. The majority
of the transmembrane segments solved in Cryo-EM structures and X-ray solved structures
display the closed state of the channels. Recently, the open state of the transmembrane
segments of AMPA receptors in presence of auxiliary proteins has been solved giving us an
insight of the open channel state (28). Whereas that of kainate receptors still needs
investigations. Our investigation has provided the information about the conformational
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changes at the transmembrane segments of heteromeric kainate receptor GluK2/K5 at
different conditions, which are discussed in Chapter 4 and Chapter 5.

1.4

Dissertation objective and overview

The main objective of this dissertation is understanding the conformational control
of function in the kainate and NMDA receptors. For this I have used a combination of
techniques, molecular dynamics simulation and single-molecule FRET (fluorescence
resonance energy transfer) spectroscopy that allow me to study the dynamics and
conformations that the proteins occupy, which is then correlated to functional states
through electrophysiological investigations. Specifically, using these methodologies I have
studied the conformational control of gating, allosteric modulation, partial agonism and
cooperativity between agonists. The chapters in this dissertation are mainly focused on
following investigations.

1.4.1

1.4.1.1

Investigations on kainate receptors

Structural arrangement and dynamics

The heteromeric form of kainate receptors GluK2/K5 despite its abundant
occurrence are less studied. The only available structural data for GluK2/K5 is its isolated
ATD which is not sufficient to understand the subunit arrangement of a full-length
GluK2/K5 as well as its structure-function relationship. Using single molecule FRET, we
have identified the specific arrangement of GluK2 and GluK5 subunit in a full-length
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receptor. In addition, we have identified the difference in the conformational arrangement
at resting and desensitized condition in a full-length receptor. These results are discussed
in Chapter 4.

1.4.1.2

Mechanism underlying partial agonism

Structures are available for isolated ABD of closely related homomeric kainate
receptors that are complexed with a variety of agonists and exhibit different degrees of cleft
closure. This differential degree of cleft closure is thought to dictate partial agonism
mechanism in kainate receptors (33, 47, 62). Whereas, in the case of most abundant subtype
of kainate receptor GluK2/K5, the mechanism of channel activation in GluK2/K5 heteromer
when bound to partial agonists is still unclear due to its insufficient structural data. Thus,
in an effort to understand the structural mechanism underlying partial agonism in
GluK2/K5 we have utilized single molecule FRET and molecular dynamics simulations and
specifically investigated the difference in the degree of cleft closure in both GluK2 and
GluK5 subunits when bound to glutamate as well as to AMPA. These are discussed in
Chapter 5.
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1.4.2

1.4.2.1

Investigations on NMDA receptors

Role of specific interface in the mechanism underlying negative cooperativity

The negative cooperativity between glutamate and glycine in GluN1/N2A NMDA
receptors has been established through functional studies and was also observed through
smFRET experiments done in our lab. The subunits GluN1 and GluN2A in NMDA receptors
are arranged as dimer of dimers and hence, there are two interfaces involved in the
interaction between these GluN1 and GluN2A subunits. In Chapter 6, I will discuss about
the role of these specific interfaces in mediating the mechanism underlying negative
cooperativity utilizing molecular dynamics simulations.

1.4.2.2

Role of P532H mutation in human NMDA (GluN1/N2A) receptors

This is a collaborative work done with a team at Emory University. A mutation P532H
in GluN1 of NMDA receptor was seen in a female patient showing neurodevelopmental and
movement disorders. The team at Emory University did functional analysis and found that
the mutation significantly decreased glutamate potency. In Chapter 6, I will discuss my
work using molecular dynamics simulations that provided the structural mechanism
underlying this functional deficiency.
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METHODS

2.1

Single molecule Förster Resonance Energy Transfer (smFRET)

Part of this chapter is taken with permission from the research article “Paudyal, N.,
Bhatia, N. K., & Jayaraman, V. (2021). Single molecule FRET methodology for
investigating glutamate receptors. Methods in enzymology, 652, 193–212”

2.1.1

Introduction to smFRET

Förster Resonance Energy Transfer (FRET) is a form of non-radiative energy transfer
between two fluorophores, with one acting as a donor and the second as an acceptor. The
efficiency of energy transfer serves as a biological ruler when the two fluorophores are
covalently attached to sites of interest within a biomolecule because the efficiency varies
with the distance between the fluorophores (63). The power of FRET to study
conformational dynamics was significantly enhanced when molecules could be studied at
the single molecule level (64). Using FRET at the single molecule level (smFRET) allows us
to perform measurements beyond ensemble averages and assess the diverse heterogeneous
conformations that biomolecules can populate (64). Unlike conventional methods of
structural investigations, smFRET has the ability to study protein conformation as a
function of time, thus allowing for investigating the conformations and kinetics of the
transitions between conformations (65, 66). The use of smFRET has been reported in the
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research of fundamental biological processes such as DNA replication, transcription,
translation, RNA folding, and ion channels (66-69). In this chapter, we focus on the
methodology that we have adapted for performing smFRET measurements on ionotropic
glutamate receptors and discuss strategies for labeling, protocols for sample preparation,
data acquisition, and analysis.

As discussed in the previous chapter there is extensive structural information available
for the glutamate receptors. These structures provide an excellent foundation of the endstate conformational changes associated with the glutamate-mediated channel opening,
desensitization, and modulation by small molecules and auxiliary proteins in these
receptors. On the other hand, single channel recordings of these receptors provide detailed
mechanistic insight into the gating mechanism under the above conditions and show
multiple intermediates between the resting, open, and desensitized states. To be able to
map structures to the functional states identified through the single channel recordings it
becomes essential to use a single molecule method such as smFRET. smFRET can provide
insight into the heterogeneous population of conformational states in the open, inhibited,
and desensitized states associated with agonists, allosteric modulators, and auxiliary
protein binding in iGluRs (69-72).
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2.1.2

2.1.2.1

Experimental design for the application of smFRET on iGluRs

Labeling strategy in iGluRs

In order to address the specific question of interest, the first major hurdle for doing
smFRET measurements is choosing the appropriate sites for labeling the protein of interest.
The near atomic resolution structures available for these receptors offer us an advantage
when selecting sites for smFRET measurement. For labeling strategy, we should identify
sites that (1) reflect the conformational changes associated with the conditions being
studied, (2) have minimal cross talk with sites on other subunits (in the context of the
tetrameric receptor), (3) are solvent-exposed to increase the ease of labeling, (4) do not
affect the function, and (5) are at the appropriate FRET distance for known donor-acceptor
FRET pairs. With respect to the ideal distance between the donor and acceptor sites, the
relationship between FRET efficiency and distance for a given donor-acceptor pair is
dictated in part by the overlap integral (J) between the donor emission and acceptor
absorption, which in turn dictates the distance at half maximal FRET efficiency (R0) (73) as
shown in equation 1 and 2.
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Figure 2-1. Spectral profile of fluorophores and FRET efficiency as a function of distance
(A) Spectral profile of donor (Alexa 555) and acceptor (Alexa 647). The spectral overlap
region is shown in yellow and lies between the donor emission (solid magenta) and
acceptor excitation (dotted blue). (B) FRET efficiency as a function of the distance
between donor and acceptor fluorophores (R). In the given equation, R0 represents the
Förster distance at which the FRET efficiency (E) is 50%. The Förster distance value for
Alexa 555 and Alexa 647 is 51 Å.
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Where, E:;<= refers to the FRET efficiency, 12 is the quantum yield of the donor, 4
is the refractive index of the media, / is the orientation factor, and R is the distance between
the donor and acceptor sites. For smFRET measurements, it is preferable to have sites that
would give 50% to 90% FRET efficiency (Figure 2-1), as this region shows large changes in
FRET efficiency associated with changes in distance and also has adequate FRET photons.

The donor and acceptor fluorophores selected for labeling should have high
quantum yield values, high photostability, and sufficient spectral overlap between donor
emission and acceptor excitation (73). Some examples of smFRET dyes for donor and
acceptor pairs are Alexa 555-Alexa 647, Cy3-Cy5, Cy5-Cy7, and Atto550-Atto647N.

There are several general schemes available for site-specific labeling of proteins with
fluorophore pairs. Given that iGluRs do not have a large number of extracellular accessible
cysteines (1-5 in the different subtypes), we have used cysteines as sites for attaching the
donor and acceptor fluorophores. In order to introduce cysteines at specific sites, the
solvent accessible non-disulfide-bonded extracellular cysteines are mutated to serines. This
background construct is tested to ensure there is no fluorescence when tagged with thiolreactive fluorophores (e.g., maleimide dyes) and its functionality is verified using
electrophysiological measurements. Then cysteines are introduced at sites identified for
investigating specific conformational changes as discussed above. The functionality of this
construct is verified before any smFRET investigations are performed. Since there are 2 to 4
cysteines (depending on the sites being labeled), the immobilized protein will have
molecules showing multiple donor and acceptor fluorophores. The number of fluorophores

25

can be determined based on the number of photobleaching steps. Only those protein
molecules that show both a single donor and a single acceptor photobleaching step are used
for the FRET analysis; this is to ensure that only a single distance is being measured.
Additionally, FRET between the acceptor and donor is clearly evident in those traces where
acceptor photobleaching occurs first and results in donor intensity increasing due to the
donor’s inability to transfer energy to the acceptor after the acceptor has photobleached.
An alternate strategy for attaching fluorophores at specific sites is the use of unnatural
amino acids which can be introduced with specific chemistries that are different from the
canonical amino acids (74). This has the advantage of not requiring deletion of inherent
cysteines, but the disadvantage is the lowered protein expression typically seen in these
cases (75). Figure 2-2 shows sites in iGluRs that we have used for Alexa 555 maleimide dye
and Alexa 647 maleimide dye as donor and acceptor fluorophores, respectively. These sites
satisfy the constraints listed above and are optimal for smFRET experiments.
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Figure 2-2. Overview of iGluR structure and fluorophore labeling sites.
Side view of an iGluR tetramer showing subunit and domain arrangement in left panel.
The right panel shows the top-down view of the amino-terminal domain, agonist-binding
domain, and transmembrane domain, depicting the sites chosen for labeling for smFRET
experiments. In a multidomain protein like an iGluR, one domain is labeled at a time at
sites highlighted in magenta to study the conformational changes induced in that
particular region of a full-length receptor. Structure image was created using Visual
Molecular Dynamics (VMD) software. Solid red lines between two fluorophore labeling
sites indicates sites in close proximity where FRET is expected. Red dotted lines between
sites represent large distances where no FRET is observed. Black dotted site represents
sites in closer proximity causing possible cross talk between fluorophores.
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2.1.2.2

Immobilization of labeled protein onto microscope slides:

smFRET can be performed either in freely diffusing molecules or using protein
immobilized on a glass slide (73, 76). For smFRET on the full-length iGluRs, we have
immobilized the receptor on to a streptavidin-coated glass side using either biotinylated
antibodies specific to an epitope on the receptor or with a twin-strep tag introduced in the
receptor. Prior to applying the protein for immobilization, we clean the glass slide with a
soap solution in an ultra-bath sonicator to remove any dirt particulate matter, followed by
a mixture of ammonium hydroxide and hydrogen peroxide (Tl-1 solution) to hydroxylate
the slides and achieve a hydrophilic glass surface. We then expose the slides to high energy
plasma that breaks down and oxidizes the organic surface contaminants, which can be
removed using flowing gas. Next, we functionalize the clean slides with amine and silane
groups using 3-aminopropyltriethoxysilane (Vectabond TM reagent) and conjugate with the
ester group of PEG-N-Hydroxysuccinimide (NHS) esters. The PEG coating makes the slide
surface hydrophilic and thus prevents the nonspecific hydrophobic interactions of proteins
with the slide surface (77). For the PEG coating we treat the slides with a mixture of biotinPEG-NHS (NHS-PEG4-Biotin) and PEG (mPEG-succinimidyl carbonate: mPEG-SC)
overnight where the biotin-PEG serves as the binding site for streptavidin. On the day of
the experiment, we treat the slides with short-chain methyl-PEG NHS ester for 2-3 h to
ensure complete coverage of the glass slide. We apply streptavidin to PEG coated slides to
bind to the biotin-PEG, and the streptavidin serves as the anchor for binding biotinylated
antibodies specific to the protein of interest or twin-strep-tag introduced in the protein.
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Figure 2-3. Schematic outline of the smFRET protocol.
(A) Sample preparation—Transiently transfected (8 µg of GluK2 DNA + 12 µg of GluK2
DNA) cells are first harvested and then labeled with Alexa 555 and Alexa 647
fluorophores. The cells are then solubilized and spun down using an ultracentrifuge to
collect the supernatant for use as smFRET sample. (B) Slide preparation—An adhesive
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Hybriwell chamber and two tubing connectors are applied to an ultraclean PEG-treated
quartz slide. Streptavidin is applied to the slide to facilitate twin-strep tag-based
immobilization. Finally, the sample is applied to the slide. (C) Data acquisition—A
confocal fluorescence lifetime microscope is used to collect the data. The emitted
photons from the immobilized sample can be spotted through the donor and acceptor
channel. The FRET channel will allow us to select single molecules for our study. (D) Data
analysis—Typical time trace of a single molecule showing single photobleaching step
between donor (blue) and acceptor (pink) and anticorrelation with each other. Partial
trace (green) of a single molecule before photobleaching is taken to prepare a FRET
efficiency histogram. In general, 45–50 molecules are taken for making cumulative FRET
efficiency histograms to know the complete structural landscape as well as estimate the
number of FRET states.

2.1.3

2.1.3.1

Step-by-step method details

Sample preparation

Use the jetPRIME transfection protocol to transiently transfect HEK 293T cells with
both

8 µg of GluK2 DNA and 12 µg of GluK5 DNA per 10 cm dish and incubate for 24-48

h at 37 °C. Two 10cm dishes can be used for transfection (Figure 2-3). Scrape the transfected
cells and transfer into 50 mL conical tubes. Harvest the cells using the centrifuge at 1100 g
at 23°C for 3 min. Use ECB to wash and resuspend the cell pellet, transfer it to a 15 mL conical
vial and spin down. Then, wash the cells thrice with (~3 mL) ECB. After washing, resuspend
the cell pellets in 3 mL of ECB and label the cells with premixed 600 nM of donor
fluorophore and 2.4 µM of acceptor fluorophore at room temperature for 45-60 min. Cover
to prevent photobleaching of fluorophores. Following labeling, repeat the cell wash with
ECB 2-3 times. Solubilize the cells with 2 mL of solubilization buffer and nutate for 1 h at
4°C. Add protease inhibitor (PI) to the solubilization buffer just prior to solubilization to
reduce the rapid degradation of the protein due to endogenous protease present in the HEK
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293T cells. After solubilization, transfer the crude lysate to an ultracentrifuge tube and spin
down for 1 h at 100,000 × g at 4°C and use the supernatant as smFRET sample. Apply smFRET
sample to the slide immediately for data collection and preserve the remaining sample at
4°C if needed for additional slides.

2.1.3.2

Slide preparation

Use the bath sonicator to clean the silicone templates with methanol placed in a beaker
for 30 min. Transfer the silicone templates to a conical tube containing 50 mL of methanol,
vortex, and store the templates by adding clean methanol to the tube. Clean 20 mm × 20
mm microscope cover glasses using bath sonication in a 5% solution of Liquinox phosphatefree detergent for 10 min and subsequently by molecular-biology grade water. Repeat the
sonication step for cover slides in the presence of acetone followed by cleaning with
molecular-biology grade water. Place the coverslips in a beaker containing Tl-1 solution and
incubate at 70°C for 5 min. Wash the slides with purified water and dry with a gentle flow
of nitrogen. Place the slides in a metal holder and transfer them to the Harrick Plasma PDC32G Plasma Cleaner for plasma cleaning. Operate the vacuum pump and wait for the
chamber pressure to drop to below 200 mTorr. Use oxygen to flush the chamber 3 times
and maintain the pressure stability below 200 mTorr each time after flushing. Again,
perform the plasma cleaning of slides for 2 min, release the vacuum, and get the slides.
Prepare the solution of Vectabond and acetone in a ratio of 1:40 by volume on the day of
use and submerge the slides in the solution for 5 min. This is the step for aminosilanization.
Then dry the slides with a gentle flow of nitrogen and store them under vacuum. (Note: A
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new Vectabond bottle once open can be used for two weeks and must be handled and stored
in nitrogen). A day before each experiment, clean the silicone templates stored in methanol
with a nitrogen flow and place the silicone template on the slide with an oval area of the
template placed at the center of the slide. Add overnight PEG solution to cover the oval area
of the slide (typically 50 µl should be enough). Then, put the slide in a petri dish and
incubate overnight in a dark space at room temperature. On the day of the experiment,
clean the overnight PEG-treated slide with water and dry it with nitrogen. Apply short-chain
PEG solution to completely cover the oval area of the slide and incubate for 2-3 h at room
temperature. Wash the slide with purified water and dry with nitrogen. Mark the position
of the oval area at the back of the slide and remove the silicone template. Apply adhesive
Hybriwell chamber to the slide and two press fit tubing connectors at the ports of each
chamber. Prepare streptavidin solution and inject the solution through the inlet chamber
into the slide until the solution comes out through the outlet chamber (we use around 3550 µl). This is to ensure enough solution flows over the slide and covers the oval area during
streptavidin coating. Incubate the slide for 10 min and then flush out the solution by
washing the slides with 1×PBS 2-3 times. As mentioned earlier protein can be immobilized
either by using biotinylated antibody specific for an epitope in the protein or via twin step
tag introduced in the protein. For biotinylated antibody-based immobilization, first apply
secondary antibody to the slides and incubate the slides at 4°C for 20 min. Then, wash the
slides with 1xPBS and apply primary antibody to the slides. Incubate the slides further for
20 min at 4°C and then wash with PBS. Apply BSA solution and incubate for 20 min at 4°C.
Finally wash the slides with 1xPBS. Skip this step of antibodies (secondary and primary) and
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BSA treatment for twin-strep tag-based immobilization. Now, apply protein sample to the
slide and incubate for 20 min at 4°C. Wash the slide by passing ROXS solution through the
chamber 2-3 times. (Note: While injecting solution to the slide through connectors, one
should make sure that no bubble is trapped in the slide because the presence of bubbles makes
labeling of the slide inconsistent.). The slide is now ready for imaging.

2.1.4

Microscope setup and data collection

A PicoQuant MicroTime 200 Confocal Fluorescence Lifetime Microscope is used
with pulsed interleaved excitation (PIE) set at an 80 MHz pulse rate to excite the
fluorophores through 532 and 637 nm lasers for data collection. The slide positioned with a
x-y-z piezo scanning stage is observed through an oil-immersed 100× objective lens. The
photons emitted through the sample travel back to the objective lens and pass through two
550 and 650nm emission filters before being detected by two SPAD photodiodes. The
emission filters facilitate the visualization of the donor and acceptor channels. The
schematic representation of the microscope setup is shown in Figure 2-4. To increase
photostability of fluorophores the sample slide is flushed with a reducing and oxidizing
system (ROXS). The ROXS buffer has glucose, pyranose oxidase, and catalase as oxygen
scavengers and triplet state quenchers that includes an oxidizing agent (methyl viologen)
and a reducing agent (ascorbic acid). The oxygen scavenging system removes the oxygen
from the solution, thus minimizing the photobleaching caused by the excited state reactive
oxygen species (78). The triplet state quenchers generate radical ions from the triplet state
of the fluorophore by electron transfer. The oxidation of radical anion or reduction of radical

33

cation leads to the recovery of the singlet-ground state fluorophore. The depletion of the
triplet state keeps a check on the blinking of the fluorophores.

Figure 2-4. Experimental setup of smFRET confocal microscope.
Excitation light from the laser source is reflected by the dichroic mirror through the
objective and into the smFRET sample. The emitted photons from sample fluorescence
then travel back through the objective lens and pass through the dichroic mirror. The
adjustable pinhole of size 50 μm is used to increase the spatial resolution of the emitted
light obtained from sample fluorescence. The emitted light then passes to the longpass
beamsplitter, which reflects photons below 635 nm wavelength to SPAD 2 and allows
photons above 635 nm wavelength to pass to SPAD 1. Bandpass filters are used in front of
each SPAD to ensure that only donor fluorescence is observed at SPAD 2 and only
acceptor fluorescence is observed at SPAD 1. A charge-coupled device (CCD) camera is
used to observe back-reflected light from the objective and ensure a good focus on the
slide.
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During data collection scan a 20 µm × 20 µm area of the sample slide using the
confocal microscope and check the focus of the microscope prior to imaging. For the
molecules selected, record their fluorescence intensity, and only keep those molecules that
exhibit a single acceptor and single donor photo-bleaching step as well as anti-correlation
between donor and acceptor. If cysteines are used as labeling sites for the donor and
acceptor fluorophores (as we did for iGluRs) perform control experiments with protein
lacking the cysteine sites and labeled with fluorophores. This control checks for non-specific
labeling of fluorophores.

2.1.5

Quantification and statistical analysis

Only those molecules that show a single photobleaching step between acceptor and
donor as well as an anticorrelation with each other are subjected to further analysis (Figure
2-3D). The FRET efficiency occurrence histograms are calculated from the donor and
acceptor fluorescence intensities from 50 or more molecules that show such single
photobleaching steps. Further processing of the FRET efficiency traces is required to
denoise the raw data and estimate the number of FRET states. For this, we use the code
developed by the Landes Research Group (http://www.lrg.rice.edu/Content.aspx?id=96) for
denoising and step transition and state identification (STASI) (79) analysis that can be used
in MATLAB.
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2.1.5.1

Denoising

Denoising of raw FRET data is a critical step in allowing us to identify transitions in
the smFRET traces. There are several methods that can be used to denoise smFRET signals
to process the single-molecule data and separate the actual signal from the experimental
noise. Landes et al. also demonstrated using smFRET trajectories that wavelet transform
can improve the accuracy of this method by 200% (80, 81). Wavelet transform is a
mathematical transformation that decomposes the time domain signal into scaling and
wavelet functions. This denoising method involves three main steps: (1) Constructing a
mathematical function (basis set) to represent the signal in the wavelet domain, (2) Setting
up a threshold for the coefficients corresponding to the wavelet function to suppress the
contribution of quantifiable noise components, and (3) Performing the wavelet transform
inversion to obtain the denoised signal in time domain. A complete MATLAB package for
denoising the smFRET data is available at this webpage: www.lrg.rice.edu. Wavelet-based
denoising can also be performed using other graph software such as OriginLab that have
built in algorithms for this.

2.1.5.2

Estimation of conformational states

Various methods are available to estimate the number of states from smFRET traces
such as Hidden Markov modelling (82, 83), change point analysis (84, 85), and STaSI (38,
66, 79, 86). One of the advantages of the STaSI method developed by the Landes group is
that it does not require prior knowledge of a number of expected states. StaSI first breaks
down the smFRET trace into different segments based on the number of transition points
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and applies a Student’s t-test on each identified segment until no further step transitions
are detected. After this, StaSI performs a number of iterations on the final output from the
step identification process to group the similar states into one state. The minimum
descriptive length (MDL) function is then used to determine the optimum number of states.
For this, the MDL function first measures the goodness of fit and complexity of fit for the
model. Then, after multiple iterations, the optimal number of states are identified and
corresponds to the global minimum of the MDL value. Gaussian curve fitting of raw smFRET
histograms using Origin Software can also be performed in addition to StaSI for validating
the number of estimated states.

2.1.6

Advantages

One of the advantages of smFRET is the ability to investigate heterogenous
populations that may be lost in ensemble averaging. This technique also has the ability to
provide insight into the kinetics of the conformational changes that occur in the millisecond
to second time scale from the FRET time trajectories. Additionally, the high sensitivity of
this technique enables investigations of proteins at low sample concentrations. This method
also requires minimal sample purification technique and can be used with a wide range of
solution conditions. The versatility of this tool and reasonable cost in assembling of this
technique makes it a valuable tool for studying conformational dynamics of biomolecules.
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2.1.7

Limitations

The fluorophores are larger than the side chains of the amino acids and distances
measured are between the fluorophores. Hence, this must be taken into consideration when
measuring absolute distances. k, the orientation factor is assumed to have a mean value of
2/3 for random orientation. Errors in this assumption can be determined by measuring
anisotropy for the fluorophores attached to the site on the protein (see Haas et al for details)
(87). The time resolution for the technique is limited by the number of photons and when
using Alexa 555 and 647 dyes in the iGluR system we find that binning in 5 ms provides good
signal-to-noise ratio

2.1.8

Optimization and troubleshooting

Since cysteine mutations are introduced in the protein for fluorescence labeling,
optimal conditions for expression should be determined by using western blotting. On the
other hand, the length of time for labeling with donor and acceptor fluorophores depends
on the site being labeled. This can be optimized by using a spectrofluorometer to monitor
extent of labeled protein after removing unlabeled fluorophore with a desalting column.
Sometimes the donor and acceptor spots are observed, but no FRET is observed. This result
could imply that the distance based on the structures is not accurate and that the
fluorophores are further apart. To determine if this is the reason fluorophores with higher
R0 can be used.
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2.1.9

Summary

The advent of the smFRET technique has enabled the understanding of structural
dynamics of complex biological macromolecules, such as glutamate receptor ion channels,
on a sub-millisecond timescale. Its ability to perform measurements on a single molecule
level has facilitated a comprehensive structural understanding of the gating mechanism of
iGluRs, allowing us to correlate to its structure-function relation. The minimal membrane
purification strategy has allowed us to perform smFRET measurements without losing
sample yield. However, one should take careful consideration during fluorophore selection,
data acquisition, and data analysis to reduce the potential artifacts. In due course, if the
smFRET-guided

measurements

are

utilized with

computational

simulations

of

biomolecules, it will open the platform to investigate the biomolecule dynamics at even
smaller time scales and with greater details.

2.2

Molecular Dynamics Simulation

Molecular dynamics (MD) simulations depend on the motion of the particle as a
function of time and provides us the physical basis of structure-function relation in
biomolecules. The use of MD simulations allows us to explore the comprehensive dynamics
of every atom in a protein in silico, which cannot be easily accessible through techniques
involved in vitro or in vivo (88, 89). For MD simulations, the first step required is the use of
static biomolecule coordinates which can be obtained from solved structures such as from
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the protein data bank (PDB) or by homology modeling. Then random velocities are assigned
to the atoms in accordance with the Boltzmann distribution of energies at a defined
temperature (90). The molecular force field (for e.g., the CHARMM force field) is
introduced to calculate the forces and potential energies of the system, followed by the
calculation of Newton’s equations of motion to obtain molecular trajectories as a function
of time with coordinates and velocities updated every two femtoseconds of a simulation
time step (91). The periodic boundary condition is introduced in the simulation where the
biomolecule is enclosed in a unit cell and replicated to infinite periodic translation. By doing
so, each particle in a system is allowed to freely diffuse by entering one box and leaving the
other such that there is no wall effect (92). The system is generally assembled in a water box
consisting of ions to mimic the cellular environment. Simulation minimization is performed
to achieve local energy minima and adjust structure to the introduced force field (91).
Equilibration followed by minimization allows the stable distribution of kinetic and
potential energies in the system to attain global minima (91). Finally, the simulation
production is performed to investigate the structural and dynamic properties of the system.
The generalized scheme for performing MD simulation in a biomolecule is shown in Figure
2-5.

2.2.1

Limitations of MD simulations

Despite the success of MD simulation in facilitating the understanding of the
structural dynamics of biomolecular structures, some of the major limitations of this
technique includes, sampling limitations of the conformational space which is increased
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more with the complexity of the biomolecular structure used for the simulation. Several
computational groups have worked in addressing this sampling limitations. All atomic MD
simulations over a greater time scale involves high computational demands. Steered MD
simulation, and coarse-grained MD simulation can be utilized to address this
limitation. Another limitation can be regarding accuracy of the force field in classical MD
simulation systems which requires quantum effect. Use of hybrid quantum-mechanical
calculations can be useful to overcome this challenge.
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Figure 2-5. Schematic representation of MD simulation.
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OVERVIEW OF KAINATE RECEPTORS

Kainate receptors, as discussed in Chapter I, belong to the iGluR family forming
cation channels across the transmembrane upon glutamate binding. The cloning of the first
kainate receptor gene was reported in 1990 (93) followed by the cloning of other kainate
receptor genes shortly after. There are five subunit subtypes of kainate receptors and based
on their affinity to agonist kainate these subunits are classified as- a) low affinity kainate
receptors consisting of GluK1, GluK2 and GluK3 subunits showing 70-80% of sequence
homology with each other and b) high affinity kainate receptors consisting of GluK4 and
GluK5 subunits showing 68% of sequence homology with each other. However, the
sequence homology of GluK1-3 with GluK4-5 is only around 40% (94). The low affinity
subunits can form both homomeric and heteromeric assemblies. Whereas the high affinity
subunits require low affinity subunits to form heteromeric assemblies and cannot form
homomeric assemblies on its own (94). In addition to the variety of kainate receptors
formed due to the combination of different subunits subtypes, the subunits of kainate
receptors can also undergo alternative splicing and post-translational modification adding
more diversity to its receptor subtypes (95-100).

3.1

Distribution of kainate receptors

Historically, electrophysiological studies, immune-histological studies, and use of
subunit-specific antibodies have been used to understand the distribution of kainate
receptor subunits in the mammalian brain (98, 101). Kainate receptors are generally found
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in the central nervous system and the peripheral nervous system with varying expression
level of subunits in different regions of the brain (98, 101-103). The overlapping of the
expression of different kainate receptor subunits in the brain indicates the potential
formation of functional heteromeric kainate receptors. The specific distribution of each
subunit in the mammalian brain is listed in Table 3-1.

Table 3-1. Distribution of Kainate receptors genes in the mammalian brain and behavioral
study linked to knockout of each gene
Subunit
subtypes
GluK1

Distribution

GluK2

Cerebellar granule cells, dentate
gyrus, and interneurons, principal
cell layers of CA1 and CA3 in
hippocampus, striatum, cortex
(102, 109, 110)

Decrease in social interaction, and fear
response, increase in seizure
susceptibility, deficit in motor function
and cognitive function (107, 111, 112)

GluK3

Expressed in low levels compared
to other subtypes and found in
cortex, striatum, cerebellum
inhibitory neurons (110)
CA3 pyramidal neurons and
dentate gyrus (114)

Impairment in motor function (113)

GluK4

GluK5

DRG neurons, Purkinjee Cells of
cerebellum, CA1 interneurons (46,
102, 104, 105)

Most ubiquitously expressed
subtype (except cerebellar
purkinjee cells and some
interneurons) (102, 110, 117)
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Behavioral studies on kainate receptor
gene knockout models
Increased scratching and anxiety,
reduced pain stimuli (106-108)

ASD-like behavior, decrease in
memory formation, reduced anxiety
(115, 116)
Impairment in motor function,
reduced pain stimuli, reduced
locomotor activity, increased
depressive like activity (112)

3.2

Implication of kainate receptors in neurological diseases:

Kainate receptors can combine to form different subunit subtypes depending on
their cellular localization and display a unique mode of functioning. The dysfunction in
these kainate receptors subtypes have been implemented in several neurological conditions.
The behavioral studies done on mouse models to understand the effect of knock out of each
kainate receptor gene has been summarized on Table 3-1. The study of mouse models with
all kainate receptor genes knocked out have shown behaviors of overgrooming, hurting and
motor function problems (113). In the DRG neurons of mouse models with chronic pain, the
expression of kainate receptor genes GluK1 and GluK5 genes have been associated to the
nociception pathways and the pain transmission likely to be mediated due to GluK1 and
GluK5 kainate receptor subunits (118). The treatment of GluK1 specific antagonists such as
SYM 2081 and LY382884 have significantly decreased the pain associated behavior in these
mouse models (118). On the other hand, in a mouse model with temporal lobe epilepsy
(TLE) the overgrowth of neuronal synapse at MF-CA3 consisting of GluK2 and GluK5
subunits have been shown to induce the sensitivity of seizures linked to epilepsy (119). The
knock-out of GluK2 subunits or the treatment of GluK2/K5 specific antagonist UBP310 have
demonstrated the significant decrease in the development of seizures (119). In the human
patients with TLE, the upregulation of GluK1, GluK2, GluK4 and GluK5 subunits have been
reported (118). In the number of studies done to the patients associated with schizophrenia,
the decrease in the mRNA encoding GluK1, GluK2, GluK4 and GluK5 genes have been
observed whereas in GluK3 gene the role of polymorphism associated to schizophrenia has
been observed (118). Mutation in GluK2 subunit has been reported in a female child with
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cognitive and neurodevelopmental disorders (120). The biophysical analysis has shown that
this mutation has altered the normal function of GluK2 containing kainate receptor such as
homomeric GluK2 and heteromeric GluK2/K5 by making the receptors constitutively active
(120).

3.3

Functional significance of kainate receptors

The advancement in the study of kainate receptors has been slow as compared to
AMPA and NMDA receptors due to several reasons. First, the role of kainate receptors were
not primarily involved in mediating excitatory synaptic transmission as compared to AMPA
and NMDA receptors. Hence the effect of kainate receptors in neurological conditions due
to its dysfunction were thought to be less severe than caused by AMPA and NMDA receptors
dysfunction. In addition, the lack of kainate receptor specific antagonist have added an extra
difficulty in understanding its pathophysiological conditions. In the recent years, the
functional studies of kainate receptors have highlighted its importance in balancing brain
function.

3.3.1

Pre- and post- synaptic mode of action in kainate receptors

In the post-synaptic region, kainate receptors undergo distinct functional states in
mediating fast excitatory synaptic transmission similar to AMPA receptors (4). These
functional states are identified as resting state to receptor activation, followed by receptor
desensitization to receptor deactivation (4). Binding of agonist such as glutamate activate
the kainate receptors and allows the passing of ions. When the glutamate is bound to the
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receptor for a prolonged period, the receptor undergoes conformational rearrangement
leading to receptor desensitization, and during that period the receptor remains nonconductive (4). Finally, the glutamate gets released from the receptor and the receptor
undergoes deactivation (4). The excitatory post synaptic currents induced by kainate
receptors are smaller in amplitude and show slower desensitization and deactivation
kinetics than currents induced by AMPA receptors (101, 121). This property of kainate
receptor can show significant contribution towards the generation of action potential with
the prolonged window open for the transmission of ions in the postsynaptic region (101, 121).

Kainate receptors have also been found to localize in the presynaptic region and
participate in non-canonical mechanisms (122, 123). For instance, in the glutamatergic presynaptic region of MF-CA3 of hippocampus, neocortex, amygdala, and spinal-cord, when
the concentration of agonist kainate introduced is >100nM, the activation of kainate
receptor is followed by the activation of Gi/o proteins and AC/cAMP/PKA pathway resulting
in the depression in glutamate release (122). If the concentration of agonist kainate is
reduced to <100nM, the activation of kainate receptor is followed by Ca++CaM/AC/cAMP/PKA pathway resulting in the facilitation of glutamate release (122). In the
CA1 and CA3 region of hippocampus, the decrease or increase of glutamate release due to
the pre-synaptic kainate receptors have been related to the regulation of GABA release (124).
However, the mechanism regarding how kainate receptors binds to G-proteins for noncanonical mechanism, whether there are distinct types of kainate receptors involved in presynaptic function or a single kainate receptor can display dual mode of actions are some of
the questions that still need investigations.
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This bi-functional mode of action of kainate receptors participating in both
canonical and non-canonical synaptic transmission has shown the importance of kainate
receptors in modulating synaptic transmission and neuronal excitability. For this reason,
the importance of developing novel therapeutics for kainate receptors has expanded.

The majority of the functional studies of kainate receptor subunits have been
studied in vitro. The in vivo study of kainate receptors has been limited due to the overlap
in the region of expression for AMPA receptors and due to the unavailability of kainate
receptor subunit specific antagonist. The role of kainate receptors in excitatory post
synaptic current was first reported in synapse connecting MF and CA3 pyramidal cells in
the hippocampus with the use of AMPA receptor specific antagonists (125, 126). Later, the
involvement of kainate receptors post synaptic transmission was also studied at amygdala,
cortex, hippocampus, retina, and spinal cord (125-131). The excitatory post synaptic current
studied in the recombinant receptors versus gene-targeted mice shows difference in the
kinetics (132) and could be due to the presence of auxiliary subunits or interacting proteins
associated with kainate receptors (101, 105, 121, 133, 134). Another reason underlying this
difference could be due to the difference in the subunit composition of the functional
kainate receptors (135). In addition to the subunit diversity and accessory proteins involved
in modulating the biophysical properties of kainate receptors, the channel properties of
kainate receptors are also modulated by the presence of external cations required to activate
the channel (35, 134, 136-140). The difference in the biophysical properties of some of the
kainate receptor subtypes studied are discussed below.
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3.3.2

Diversity in the channel property of kainate receptor due to different subunit
composition

The study of kainate receptor subunits in the heterologous expression systems have
demonstrated that these receptors forming homomeric and heteromeric functional
receptors display unique gating properties. The functional property of homomeric GluK1
and homomeric GluK2 are different in a way that GluK1 shows faster recovery from
desensitization in presence of glutamate than GluK2 (135). Although in the case of kainate
induced response, GluK1 show slower desensitization kinetics and GluK2 induce rapid
desensitization (135). Studies have also shown that GluK1 can induce a response in presence
of ATPA, AMPA and iodowillardiine which is not seen in GluK2 (141). On the other hand,
homomeric GluK3 requires high concentration of glutamate for receptor activation because
of its low sensitivity to glutamate than as compared to GluK2. GluK3 are also known to
undergo rapid desensitization at sub-saturating concentration of glutamate (142).

As GluK4 and GluK5 subunits cannot form functional receptors by themselves, they
require GluK1-3 to form diverse heteromeric functional receptors. GluK4 and GluK5
containing receptors show sensitivity to molecules such as ATPA, AMPA and
iodowillardiine and increased affinity to glutamate and kainate (135, 141). GluK2/K5
heteromeric kainate receptors are the most abundant kainate receptor subtypes found in
the human brain (143). In presence of Na+ ions GluK2/K5 show faster rate of desensitization
than as compared to GluK2 (144). On brief glutamate application, GluK2/K5 mediate slow
decay response which is similar to the kainate receptor induced EPSC response (145). As
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such, it is thought that kainate receptor mediated EPSC could be mainly due to this most
abundantly available GluK2/K5.

3.4

Advancement in the structural studies of kainate receptors

The progress made to understand the biophysical properties of kainate receptors
have instigated the importance of investigating the structure-function relation of the
receptor to explore its complex gating mechanism. The first structure deposited for kainate
receptor subtype was the crystal structure of GluK1 ABD in 2005 (33). Until today several
high resolution Cryo-EM and X-Ray solved isolated ATD, and isolated ABD complexed with
different agonists of kainate receptor subtypes are available (33). Although challenging, the
development of Cryo-EM technique has also assisted in solving full-length structure
(excluding CTD) of homomeric GluK2 and GluK3 bound to antagonist as well as bound to
glutamate representing desensitized state (29). The availability of these structures has
served as a basis in understanding structural information such as- a) receptor arrangement
which is similar to other family of iGluRs, b) molecular mechanism regarding binding mode
of agonists in the receptor required to induce conformational changes, c) conformational
difference of a full-length homomeric receptor in antagonist bound and glutamate bound
desensitized state, and, d) difference in the degree of cleft closure observed in homomeric
GluK1 and GluK2 when bound to agonist of different efficacy (33, 47, 62). The highresolution structures of ABD have also shown the presence of external ions residing at the
ABD closer to the dimer interface. The mutation on an ion binding site based on structural
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information have altered the functional properties of kainate receptors thereby indicating
the importance of external ions in the receptor functioning (37).

Proteins are always in motion for inducing normal physiological processes. The
structural information of kainate receptors available via Cryo-EM and X-Ray techniques
typically represent the end state static structures and limits the information of protein
dynamics. The conformational changes in isolated ABD of homomeric GluK1 and GluK2
have been explored through several MD simulation studies (146-148). In other MD
simulation study done on isolated domains of homomeric GluK2 and heteromeric
GluK2/K5, the role of ions has been shown to alter the functional property of the receptor
(144). Recently, smFRET technique was utilized to understand the conformational changes
induced at the dimer interface of a full-length homomeric GluK2 in presence of different
ions in antagonist, active state and desensitized state showing the role of ions as critical
modulators in receptor function (70). While majority of the structural studies have been
done on homomeric subtype of kainate receptors. Despite being the most abundantly
available subtype, heteromeric kainate receptors GluK2/K5 are the least studied. The
functional studies of these GluK2/K5 receptors have outpaced their structural studies. The
availability of only isolated ATD of GluK2/K5 is not sufficient enough to understand the
subunit arrangement in a full-length receptor as well as its dynamics that participate in
channel gating under different conditions.

In the upcoming chapters, I will discuss my structural investigations done utilizing
smFRET and MD simulations on a full-length as well as isolated ABD of heteromeric kainate
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receptor GluK2/K5 to address the queries such as subunit arrangements, change in
conformational landscape of functionally similar yet structurally different resting and
desensitized states, changes in the conformation of ABD cleft and transmembrane segments
when different agonist binds to the receptor and mechanism underlying partial agonism.
Until the present, this is one of the first comprehensive structural study done on a fulllength GluK2/K5 kainate receptor.
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STRUCTURAL ARRANGEMENT AND DYNAMICS OF GLUK2/K5

This chapter is taken with permission from the research article “Litwin DB, Paudyal
N, Carrillo E, Berka V, Jayaraman V. The structural arrangement and dynamics of
the heteromeric GluK2/GluK5 kainate receptor as determined by smFRET.
Biochimica Et Biophysica Acta (BBA)-Biomembranes. 2020 Jan 1;1862(1):183001.”

4.1

Introduction

The majority of iGluR models available are of the AMPA and NMDA subtype with
only three available for full-length homomeric GluK2 kainate receptors, one in the
antagonist-bound form (24, 149) and two in the agonist-bound form exhibiting desensitized
state (21, 24). The structural data available for the homomeric kainate receptor has laid a
foundation for our understanding of the structural characteristics that give rise to the
unique function of kainate receptors.

The heteromeric GluK2/GluK5 kainate receptor is known to be the most abundant
kainate receptor expressed in the brain (143). Therefore, identifying the structural features
that are unique to the GluK2/GluK5 heteromer is crucial to design kainate receptor specific
compounds with therapeutic potential. Yet, the only structural models currently available
for the heteromeric kainate receptor are of the isolated ATDs (150). Functionally the
GluK2/GluK5 heteromer has shown higher glutamate sensitivity (EC50
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GluK2/GluK5

= 6 μM)

compared to the homomeric receptor (EC50 GluK2/GluK2 = 186 μM)(145, 151-154) and a faster rate
of desensitization (τdes
GluK2

GluK2/K5

= ~3 ms) compared to the homomeric receptor (τdes

= 5.8 ms) in the presence of sodium ions (144). These differences in function leave no

question that there are structural differences in the heteromeric kainate receptors that
remain largely unresolved. What is known is that the GluK2/GluK5 heteromer that localize
to the plasma membrane have a subunit stoichiometry of 2:2 and that the GluK2 ATD likely
mediate the ATD dimer-dimer interface (150, 155). Using photobleaching experiment it was
first identified that GluK2 and GluK5 predominantly assemble to form functional tetramer
with 2:2 subunit ratio and are significantly different from population with 3:1 or 1:3
complexes (155). Later sedimentation analysis done on association strength of GluK2 and
GluK5 has shown higher preference of forming heterodimers than as compared to
homodimers. This was further corroborated by the crystal structure of isolated ATD of
heterodimer assemblies consisting of one GluK2 and one GluK5 subunits (150). Additionally,
MD simulations on the homology model of isolated ABD dimer show that the heteromeric
receptor has a more decoupled dimer interface relative to the homomeric receptors (144).
However, these simulations were performed using the isolated ABD and changes in the
context of the full-length receptor as well as the conformation in the resting apo state are
not known.

FRET acts as a molecular ruler providing distances between the donor and acceptor
fluorophores attached to specific sites of a molecule, and when used at the single molecule
level allows for investigating the conformational landscape and energetics of functionally
significant dynamics within molecules (51, 52, 75, 86, 156-159). For the smFRET
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measurements, membrane preparations of cells expressing the protein used with minimal
purification, thus providing insight into the proteins in a near native conformation (51, 52,
75, 86, 156-159). Here, we have used smFRET to address the specific arrangement of the
receptor, and to understand the conformational landscape of the heteromeric receptor,
specifically the conformational landscape across the dimer-dimer interface at the ATD, the
dimer interface at the ABD and at the transmembrane segments. These sites were chosen
as they are known to play important roles in activation and desensitization in the
homomeric kainate receptor and/or the closely related AMPA receptor (36, 160-163).
Additionally, the sites at the ATD and ABD are equivalent to those that we used to study
the homomeric receptors (70), thus a direct comparison of differences between the
conformational landscape of the heteromeric and homomeric receptors can be made and
correlated to differences in function.

4.2

Results and discussion

For smFRET measurements we modified the GluK2 and GluK5 receptors to remove
accessible cysteines (C91, C199 and C432 at GluK2 subunit and C14, C88 and C270 at GluK5
subunit) as shown in Figure 4-1 (modified constructs are referred to as GluK2* and GluK5*).
Additionally, we have introduced a twin strep tag on the background of GluK5 constructs.
Since, GluK5 subunits do not express as homomeric receptors (95, 155, 164-166) performing
the in situ pull down using streptavidin on membrane preparations of HEK-293 cells coexpressing GluK2 and GluK5 subunits allows for the specific attachment of GluK2/GluK5
receptors and excludes the attachment of GluK2 homomeric receptors.
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The sites for fluorophore attachment were selected based on two criteria. Firstly, the
sites must reflect large-scale conformational rearrangements as interpreted from currently
available antagonist- and agonist-bound kainate and AMPA receptor structures. Second,
the geometry of the labeling sites within the receptor should be such that the different
distances within and across the dimer exhibit distinct and well separated FRET efficiencies
(86). Table 4-1 shows differences in FRET efficiencies calculated based on alpha carbon
distances within and across the dimer using homology model generated based on known
structures of AMPA and kainate receptors.

Figure 4-1. Arrangement of GluK2 and GluK5 subunits.
Extracellular amino-terminal domain (ATD) and agonist-binding domain (ABD) showing
the dimer of dimers configuration with domain swapping between dimers in ATD and
ABD. Accessible cysteines modified to form cysless constructs for GluK5 and GluK2
subunits are shown as black spheres. Transmembrane domain (TMD) is represented as
cartoon structure inside the membrane. A twin-strep tag is attached to the C-terminus of
GluK5 subunit shown in green.
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4.2.1

Arrangement of GluK2 and GluK5 subunit within the kainate receptor

Given that the kainate receptor subunits are arranged as dimer of dimers, the GluK2
and GluK5 subunits can be assembled in three possible configurations (Figure 4-2). To
determine the configuration(s) that the receptor occupies using smFRET, we measured
distances between sites 266 and 266 in the two GluK2 subunits, and equivalent sites 272 and
272 in the two GluK5 subunits, within the GluK2/GluK5 heteromeric receptors. These sites
were chosen based on homology models of the GluK2/GluK5 receptors generated, which
show that the distances between these sites can be used to clearly differentiate between the
possible configurations (Figure 4-3A). The functionality of GluK2*-266/GluK5* and of
GluK2*/GluK5*-272 subunits labeled with Alexa 555 and Alexa 647 fluorophores were
established using whole cell current recordings (Figure 4-4).
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Table 4-1. Summary of smFRET efficiencies and distances calculated
APO STATE
3KG2
(AMPA)
Observed
FRET
Efficiency
(Calculated
Distance Å)

Gaussian
fit

GluK2*266 GluK2*266

0.72 (43)
0.83 (39)

0.72 ±0.03
0.84 ± .004

GluK2*-479GluK5*-471

0.80 (40)
0.90 (35)

0.80 ± 0.01
0.90 ± 0.01

SITES

GluK2*-479 GluK5*-471
GluK5*-471 GluK5*-471
GluK2*-479 GluK2*-479

GLUTAMATE BOUND STATE

5KUH
(Kainate)

5KUF
(Kainate)

5VHZ
(AMPA)

4U4F
(AMPA)

5WEO
(AMPA)

Observed
FRET
efficiency
(Calculated
Distance in Å)

Gaussian
fit

0.62 (47)

-

-

-

-

-

-

0.83 (39)

0.87 (37)

0.56 (49)
0.69 (45)
0.83 (39)
0.94 (32)

0.56 ± 0.01
0.68 ± 0.01
0.83 ± 0.01
0.93 ± 0.01

0.33 (57)

0.62 (47)

0.83 (39)

0.89 (36)

Not observed

0.23 (62)

0.13 (70)

Not observed

0.20 (64)

0.22 (63)

0.25 (61)

0.20 (64)

Not observed

0.05 (82)

0.04 (87)

Not observed

0.02 (97)

0.05 (85)

0.08 (77)

0.05 (83)

Not observed

0.15 (68)

0.14 (69)

Not observed

0.11 (72)

0.12 (71)

0.15 (68)

0.24 (62)

Expected FRET
efficiency
(Distance in Å for
sites)
0.70 (44)

Expected FRET efficiency
(Distance in Å for sites)

GluK2*-523 GluK2*-523

0.96 (30)
0.83 (39)

0.96 ± 0.01
0.83 ± 0.01

0.91 (34)

-

0.85 (38)
0.94 (32)

0.83 ± 0.01
0.94 ± 0.01

0.85 (38)

0.87 (37)

0.90 (35)

0.71 (44)

GluK5*-515 GluK5*-515

0.94 (32)
0.81 (40)

0.94 ± 0.01
0.81 ± 0.01

0.91 (34)

-

0.84 (38)
0.93 (33)

0.85 ± 0.01
0.95 ± 0.01

0.85 (38)

0.90 (35)

0.91 (34)

0.87 (37)
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Figure 4-2. Possible configurations for amino-terminal domains of GluK2 and GluK5
subunits in GluK2/GluK5 heterotetramer forming dimer of dimers.
The distance calculated for K2-K2 subunits and K5-K5 subunits is based on homology
model for each possible configuration and smFRET experiment.
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Figure 4-3. Labeling sites and smFRET measurement at ATD of GluK2 subunit in a
heteromer GluK2/K5.
(A) Full-length structure of the apo state GluK2/GluK5 heteromer (homology model
made from PDB 3KG2) with the GluK2 subunits shown in blue and the GluK5 subunits
shown in green. Alpha carbon sites at GluK2*-266 are shown as red spheres (B–C)
smFRET data for GluK2*-266 sites; with two representative smFRET efficiency traces for
individual molecules shown in panel B and cumulative smFRET efficiency traces with
observed data (grey) overlaid on denoised data (red) are shown in panel C. Gaussian fits
shown in black, blue, and green, represents the smFRET efficiency states.
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Figure 4-4. FRET construct characterization.
Representative whole-cell recording for GluK2*-479/GluK5*-471, GluK2*/GluK5*515, GluK2*-523/GluK5*, GluK2*-266/GluK5* and GluK2*/GluK5*-272.
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Figure 4-5. Example smFRET fluorescent trajectory trace showing a single donor and
acceptor fluorophore exhibiting anticorrelation.

smFRET traces for constructs GluK2*-266/GluK5* exhibiting a single donor and
single acceptor photobleaching step with anticorrelation upon acceptor bleaching were
used for generating the smFRET efficiency traces for individual molecules (representative
trace shown in Figure 4-3 and example trace shown in Figure 4-5). The fractional occurrence
in the smFRET efficiency traces were then used to generate the smFRET efficiency
histogram. The number of states that best describes the dataset was determined using Step
Transition and State Identification (STaSI) (79). STaSI helps in the identification of
transitions within traces by using a t-test and determines the number of states represented
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in a dataset with a minimum description length algorithm (79), ensuring that the states
determined are statistically significant. The number of STaSI-determined states and their
relative occurrences were used as guiding parameters during the process of fitting the
Gaussian curves to the observed histograms, and this produced fits and standard error for
the fits are shown in Table 4-1. The cumulative histogram from smFRET efficiency traces
from 28 molecules, for GluK2*-266/GluK5* is shown in (Figure 4-3C). The donor and
acceptor traces were denoised using wavelet based denoising and the denoised FRET
histograms generated from these are shown overlaid on the observed histogram (Figure
4-3C). The denoised smFRET histogram shows primarily two states with a FRET efficiency
of 0.72 and 0.83, corresponding to distances of 43 Å and 39 Å. Gaussian fits of the observed
data correlate well showing efficiencies of 0.72 ± 0.03 and 0.84 ± 0.01. These distances are
close to the alpha carbon distance between the 266 and 266 residues (values are shown
in Table 4-1) as predicated when placing the GluK2 subunits proximal to each other (Figure
4-2A). Additionally, given that this distance is significantly shorter than the distance of 67 Å
expected in the configuration placing two GluK2 subunits within the dimer as seen in GluK2
homomer (PDB 5KUH), it can be concluded that the configuration with GluK2 (Figure 4-2B)
within the peripheral position the dimer does not exist in the heteromer.

smFRET experiments for the GluK2*/GluK5*-272 receptors on the other hand
showed no molecules with significant smFRET efficiency traces. 148 molecules probed
exhibited one or multiple donor steps or one or multiple acceptor steps, but no molecules
showed FRET between the donor and the acceptor. Based on this observation it can be
concluded that no significant fraction of the GluK2/GluK5 heteromeric receptors exist in
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the configuration placing the GluK5 subunits proximal to each other (Figure 4-2C) and
within a dimer (Figure 4-2B). Therefore, the full length heteromeric receptor expressed in
HEK-293 cells exists primarily in the configuration shown in Figure 4-2A.

4.2.2

Conformational landscape of the ATD and comparison with homomeric
kainate receptors

In order to correlate these FRET efficiency-based states to possible structural
changes we modeled the heteromeric kainate receptor into the known kainate and AMPA
receptor structures. The alpha carbon distances based on these models for the different
structures are listed in the Table 4-1 along with the calculated FRET efficiencies. These act
as reference points for correlations with our smFRET data (with the focus being changes in
distances and hence packing). The model of the heteromeric kainate receptors generated
from the antagonist bound structure of homomeric kainate receptor shows a slightly looser
packing at the ATD relative the antagonist bound structure of AMPA receptor, showing a
3 Å increase in distance between these two structures at site 266 across the dimer-dimer
interface. A similar distance change (4 Å) is seen between the two states at this site in the
smFRET efficiency states for the heteromeric receptor suggesting that it is possible for the
ATD to exist in two configurations with small variations in degree of coupling, and such
differing degrees of packing can be accounted for with these known structures.

While the smFRET data of the homomeric GluK2 receptors showed three states of
FRET efficiencies 0.69, 0.83 and 0.92 (70) compared to the two observed here for the
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heteromeric receptors, the most probable state of 0.83 is identical in both cases. Thus,
suggesting that the two receptors have a similar conformational arrangement of the dimerdimer interface at the ATD for the primary conformational state. The similarity in primary
conformation and lack of large-scale differences at the ATD between the homomeric and
heteromeric receptors would be consistent with the previous biochemical studies
suggesting that ATD plays a major role in assembly (150, 167).

4.2.3

Conformational landscape of the ABD

To study the conformational dynamics at the dimer interface in the ABD, we
introduced cysteines at site 479 on GluK2* and 471 on GluK5* (Figure 4-6A). These sites are
ideal as the distance between these residues are distinct within the dimer, relative to that
across the dimers. smFRET traces showing a single donor and single acceptor
photobleaching step with anticorrelation between the two were used to generate the FRET
efficiency traces, and 26–28 molecules were combined to generate the cumulative smFRET
efficiency histograms. The denoised smFRET histograms in the apo state show two states
with efficiencies of 0.80 and 0.90 (Figure 4-6C), corresponding to distances of 40 Å and 35 Å.
Gaussian fits of the observed data correlate well showing efficiencies of 0.80 ± 0.003 and
0.90 ± 0.001. These distances and changes in distances again correspond well with the
known structures of antagonist bound forms of kainate and AMPA receptors (Table 4-1).
Additionally, the smFRET data at the ABD agree with the data at the ATD showing that
there are two possible configurations in apo state, with slight variations in the degrees of
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decoupling at both domains, but that in both domains the tightly coupled state is more
favored.

Figure 4-6. Labeling sites and smFRET measurement at ABD dimer interface between
GluK2 and GluK5 subunits in a heteromer
(A) Full-length structure of the apo state GluK2/GluK5 heteromer (homology model
made from PDB 3KG2) with alpha carbon sites at GluK2*-479 (magenta spheres) and
GluK5*-471 (red spheres). (B–C) smFRET data for GluK2*-479 and GluK5*-471 sites at the
apo state (left panel) and the desensitized state (right panel). (B) Two representative
smFRET efficiency traces for individual molecules. (C) Cumulative smFRET efficiency
traces with observed data (grey) overlaid on denoised data (red). Gaussian fits shown in
black, blue, and green, represents the smFRET efficiency states.

The denoised smFRET histograms for the glutamate-bound state, on the other hand,
shows four states with FRET efficiencies of 0.56, 0.69, 0.83 and 0.94 (Figure 4-6C). Under
these conditions the receptor is primarily expected to be in the desensitized state. Gaussian
fits of the observed data correlate well showing efficiencies of 0.56 ± 0.01, 0.68 ± 0.01,
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0.83 ± 0.01 and 0.93 ± 0.01. The distances associated with each if these FRET efficiencies are
listed in Table 4-1. These FRET efficiencies span the range of distances from 49 to 32 Å
(difference of 17 Å.) The distance range for the models based on known agonist bound state
structures are 57 to 36 Å (difference of 21 Å) (Table 4-1). The range of decoupling seen in the
smFRET measurements is hence closely related to the range seen in the known structures.
However, it is interesting to note that the structure of homomeric kainate receptor structure
thought to be in the desensitized state (PDB 5KUF) shows the largest decoupling (24). The
smFRET data for the heteromeric receptor, on the other hand, shows that the largest
decoupled state in fact represents the lowest occupancy state, and the highest occupancy
state of FRET efficiency shows intermediate decoupling which would correspond to the
structure showing only slight decoupling such as that seen for the agonist bound form of
AMPA receptors PDB: 4U4F (22). These results suggest that complete decoupling of the
dimer interface is not necessary for desensitization in the kainate receptors.

4.2.4

Comparison of the conformational landscape of heteromeric to homomeric
receptors at the ABD dimer interface

While the FRET efficiencies of 0.56, 0.69, 0.83 and 0.94 in the glutamate-bound state
for the heteromeric receptors are similar to the FRET efficiencies of 0.54, 0.69, 0.82 and 0.93
seen in the homomeric GluK2 receptors, the fractional occupancy is higher for the more
decoupled state in the heteromeric receptors relative to the homomeric receptors. This shift
towards the decoupled states, indicative of decreased ABD dimer stability. The lower FRET
efficiency state with longer dimer distances are thought to favor ion dissociation and are
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also associated with faster desensitization rates (144). The smFRET results are also
consistent in trends with MD simulations which show a decoupling of the dimer interface
in the heteromeric receptor relative to homomeric receptor, however the shifts were small
showing a shift of 1 Å towards a more decoupled state (144). The lack of large changes in the
MD simulations could be due to the shorter time scales of the simulations or due to the fact
that they were performed on the isolated ABD.

4.2.5

Conformational landscape at the transmembrane segments

In order to study the conformational dynamics at the transmembrane segments we
introduced cysteines at site 523 on GluK2* and 515 on GluK5* (Figure 4-7,Figure 4-8). These
sites are positioned at the top of the first transmembrane segment, which makes them ideal
to measure the distance across the pore axis at complementary sites. smFRET traces
showing a single donor and single acceptor photobleaching step with anticorrelation
between the two were used to generate the FRET efficiency traces, and 27–31 molecules were
combined to generate the cumulative smFRET efficiency histograms. The denoised smFRET
histograms for GluK2*-523 in the apo state show two states with efficiencies of 0.83 and 0.96
(Figure 4-7C) and correspond to distances of 39 and 30 Å. Gaussian fits of the observed data
correlate well showing efficiencies of 0.83 ± 0.01 and 0.96 ± 0.01. These distances are close to
the alpha carbon distance of residue 523–523 in the two GluK2 subunits obtained from the
apo state homology model with the channel being in a closed state (Table 4-1). The smFRET
histograms for GluK2*-523 in the glutamate-bound state show two peaks with efficiencies
of 0.85 and 0.94, corresponding to distances of 38 and 32 Å. These efficiencies are similar to
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what is found under apo conditions at this site suggesting similar packing in the resting and
desensitized closed states; however, there is a significant shift in occupancy towards the
high FRET state in the glutamate bound form, suggesting the more tightly packed
transmembrane conformation is favored in the desensitized state. The tighter packing
observed under desensitized conditions differs from distances found in the homology
model (Table 4-1). These differences likely result from additional stability at the TMD due
to the retention of lipids around the transmembrane regions in measurements using the
SiMPull method (168).

Figure 4-7. Labeling sites and smFRET measurement at TMD segments of GluK2 subunit
in a heteromer GluK2/K5
(A) Full-length structure of the apo state GluK2/GluK5 heteromer (homology model
made from PDB 3KG2) with alpha carbon sites at GluK2*-523 (red spheres). (B–C)
smFRET data for GluK2*-523 sites at the apo condition (left panel) and the desensitized
state (right panel). (B) Two representative smFRET efficiency traces for individual
molecules. (C) Cumulative smFRET efficiency traces with observed data (grey) overlaid
on denoised data (red). Gaussian fits shown in black, blue, and green, represents the
smFRET efficiency states.
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The smFRET histograms for GluK5*-515 in the apo state show two states with
efficiencies of 0.81 and 0.94 and correspond to distances of 40 Å and 32 Å, and in the
glutamate-bound state show two peaks with efficiencies of 0.84 and 0.93, corresponding to
distances of 39 Å and 33 Å (Figure 4-8). These smFRET data from site GluK5*-515 are similar
to site GluK2*-523 in the glutamate-bound state showing that at this site the protein exhibits
four-fold symmetry in both the apo and glutamate-bound states.

Figure 4-8. Labeling sites and smFRET measurement at TMD segments of GluK5 subunit
in a heteromer GluK2/K5
(A) Full-length structure of apo state GluK2/GluK5 heteromer (homology model made
from PDB 3KG2) with alpha carbon sites at GluK5*-515 (red spheres). (B–C) smFRET data
for GluK5*-515 sites at apo condition (left panel) and desensitized state (right panel). (B)
Two representative smFRET efficiency traces for individual molecules. (C) Cumulative
smFRET efficiency traces with observed data (grey) overlaid on denoised data (red).
Gaussian fits shown in black, blue, and green, represents the smFRET efficiency states.
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4.3

Conclusion

There are a plethora of X-ray crystallography and Cryo-EM structural models available
for the AMPA and NMDA classes of iGluR including both isolated ATD and ABD, and also
the full-length receptors. However, only three structural models have been produced for
the full-length homomeric GluK2 receptor type. Currently, there are no structures of the
full-length GluK2/GluK5 heteromeric receptor. Using smFRET investigations, we show that
GluK2/GluK5 heteromeric receptors assemble in one configuration with the GluK2 sites
occupying proximal positions across the dimer-dimer interface at the ATD of the receptor.
Additionally, we show that the spread of conformational states is not significantly different
between the homomeric and heteromeric receptors at the dimer-dimer interface at the ATD
suggesting that the primary role of this domain is in assembly. The ABD, on the other hand,
shows more decoupling and a higher occupancy of the decoupled state at the dimer
interface in both the apo and glutamate-bound states of the heteromeric receptor relative
to what is observed in the homomeric receptor. Prior studies have shown that the
decoupling of the dimer interface at the ABD is the primary conformational change driving
desensitization. Therefore, the increase in decoupling at this interface in the ABD of the
heteromeric receptor results in easier transition into the desensitized state and ties back to
the functional studies that show a faster desensitization rate in the heteromeric receptor
relative to the homomeric receptors. The smFRET studies also show that the GluK2/GluK5
heteromeric receptors loses its two-fold symmetry seen in the extracellular domain and
exhibits four- fold symmetry at the start of the first transmembrane segment in both the
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apo and the glutamate-bound forms of the receptors, similar to the other known structures
of kainate and AMPA receptors.
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MECHANISM UNDERLYING PARTIAL AGONISM IN GLUK2/K5

5.1

Introduction

Having established the configuration of GluK2/GluK5 heteromers and with Cys-light
functional constructs for the same as discussed in the previous chapter, I had tools and
knowledge to investigate conformational transitions in this family of proteins. One
outstanding question that I investigated was how partial agonism arises in heteromeric
GluK2/GluK5 receptors. There are currently no structures of the partial agonist bound states
of heteromeric receptors and hence the mechanism underlying partial agonism is not
known.

Partial agonism in the closely related homomeric AMPA receptors has been studied
extensively. The structures of AMPA receptors bound to agonists with varying degrees of
maximal activation showed different extent of closure of the bilobed ABD cleft suggesting
that this difference in conformational change when translated to the transmembrane
segments may lead to difference in activation (40-45). Additional mutants and structures
of these mutants, however, indicated that this simplistic relationship between channel
activation and cleft closure may not be sufficient to account for partial agonism (53, 54).
Dynamics of the receptor also needed to be taken into account, and insight into this was
obtained from studies using MD simulation (169), NMR (49, 50) and smFRET (51-54). These
studies suggested local backbone dynamics and overall conformational dynamics (state to
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state conformational changes) that dictate fraction of population occupying tightly closed
cleft conformation ultimately controlled activation.

Here I decided to use a similar approach of combination of MD simulations and
smFRET to study the mechanism underlying partial agonism in heteromeric GluK2/K5
kainate receptors. In the case of the heteromeric GluK2/K5 kainate receptors there is an
additional layer of complexity, namely difference between the GluK2 and GluK5 subunits.

Previous functional studies show that AMPA do not induce any response in
homomeric GluK2 receptors, but act as partial agonist in the heteromeric GluK2/K5, (105,
117, 141, 170). So, one question is whether these agonists exert partial activation by binding
only to GluK5 and not GluK2, or if GluK2 subunits are able to bind to these agonists in the
presence of GluK5 due to difference in the GluK2 structure and dynamics in the context of
the GluK5 subunit. To answer this question and to determine the mechanism of partial
agonism by the ligand AMPA in GluK2/K5, we utilized smFRET and MD simulations and
investigated the change in the conformational landscape of ABD cleft in both GluK2 and
GluK5 subunits when bound to full agonist glutamate, partial agonist AMPA and no ligand
bound condition. Further, we investigated how the change in the degree of cleft closure in
GluK2 and GluK5 subunits in a full-length receptor when bound to AMPA translate to the
conformational changes at the transmembrane segments which in turn could be translated
to the functional changes in terms of activation of GluK2/K5.
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5.2

5.2.1

Results

Conformational changes at ABD of Gluk2/k5:

To understand the difference in the conformational landscape of GluK2 and GluK5
subunits in a heteromer GluK2/K5 when bound to glutamate, AMPA and in no-ligand
bound condition we first did smFRET measurements at glutamate bound, AMPA bound,
and no-ligand bound conditions to understand the conformational landscape of ABD cleft
on a full-length receptor. To further confirm the trend of cleft closure observed during our
smFRET measurements and understand the detailed binding mechanism of AMPA to GluK2
and GluK5 cleft, we did MD simulations on an isolated ABD dimer. Then to elucidate on
how binding of different agonist on a receptor translates to the channel opening and how it
contributes to the unique functional behavior of the receptor, we did smFRET
measurements at the transmembrane segments of both GluK2 and GluK5 subunits on a fulllength receptor.

5.2.2

Changes at the ABD cleft as observed in smFRET measurements

For smFRET measurements at the ABD, we first introduced cysteines for
fluorophores attachment by mutating sites 402 and 679 at GluK2* subunit (Figure 5-1A) and
sites 395 and 673 at GluK5* subunit (Figure 5-2B). These sites will allow us to calculate the
distance across the cleft in ABD and will help us to investigate the conformational changes
induced in the ABD when bound to different agonist. Next, we selected our single molecules
based on single acceptor and single donor photobleaching and showing anticorrelation
75

between the donor and the acceptor. We represented the data of 50-60 single molecules
collected in the form of cumulative FRET efficiency histogram (Figure 5-1B-D and Figure
5-2B-D) and concatenated FRET efficiency traces (Figure 5-3). Through these data, we were
able to study the spread of FRET efficiency conformational states of both GluK2 and GluK5
ABD cleft in a full-length receptor in glutamate bound, AMPA bound, and no-ligand bound
condition. The cumulative histograms were denoised using wavelet based denoising and
the preferred FRET efficiency states were identified using gaussian fitting to the cumulative
histogram. The guiding parameters for gaussian fitting were taken from the states identified
using STaSI (Step transition and state identification). The functionality of the smFRET
constructs were verified using whole cell recordings (Figure 5-4).
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Figure 5-1. smFRET measurements at GluK2 Cleft.
A) Fluorophore labeling sites across the ABD cleft (red spheres) in a GluK2 subunit (blue)
of a full length GluK2/K5 (PBD 7KS0). B-D) Cumulative smFRET efficiency histogram
data for GluK2 cleft in presence of glutamate (B), AMPA (C), and no-ligand (D) is
prepared by overlaying both observed and denoised data. Gaussian fitting (black curve)
is done on observed data to represent the preferred FRET efficiency states
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Figure 5-2. smFRET measurements at GluK5 Cleft.
A) Fluorophore labeling sites across the ABD cleft (red spheres) in a GluK5 subunit
(green) of a full length GluK2/K5 (PBD 7KS0). B-D) Cumulative smFRET efficiency
histogram data for GluK2 cleft in presence of glutamate (B), AMPA (C), and no-ligand
(D) is prepared by overlaying both observed and denoised data. Gaussian fitting (black
curve) is done on observed data to represent the preferred FRET efficiency states
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Figure 5-3. Concatenated smFRET efficiency traces for measurements across GluK2 cleft (top panel) and GluK5 cleft
(bottom panel).
These traces are utilized for preparing cumulative FRET efficiency histogram shown in Figure 5-1 and Figure 5-2.
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Figure 5-4. Whole cell recordings for the functional validation of smFRET
constructs

5.2.2.1

Changes observed at sites across GluK2 cleft

The cumulative FRET efficiency histogram (Figure 5-1 B-D) as well as concatenated
smFRET efficiency traces (Figure 5-3 A) across the cleft of ABD at GluK2 subunit in all
glutamate bound, AMPA bound, and no-ligand bound conditions show that the
conformational population distributes mainly in three FRET efficiency states. In glutamate
bound condition, we observed that the conformational landscape of GluK2 ABD cleft
occupies primarily high FRET efficiency states 0.94, 0.84, and occasionally 0.72
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corresponding to a distance of 32.2Å, 38.7Å, and 43.6 Å respectively. This suggests GluK2
cleft when bound to glutamate favor shorter distance between sites across the cleft and
hence tight cleft closure. The FRET efficiency state of 0.84 (38.7Å) when bound to glutamate
agrees well with the cleft distance 36.7Å of GluK2 subunit in a glutamate bound GluK2/K5
Cryo-EM structure. In an AMPA bound condition, the GluK2 cleft conformation is seen to
spread between FRET efficiency states 0.89, 0.78 and 0.67 whose distance corresponds to
value 36Å, 41.3Å, and 45.3Å respectively. The shift of population is more towards FRET
efficiency state 0.89 and 0.78 and only partly towards FRET efficiency state of 0.67
suggesting that the extent of cleft opening is more when bound to AMPA than when bound
to glutamate. In no-ligand bound condition, we observed the conformational population
occupying FRET efficiency states 0.87, 0.77, 0.67 corresponding to distance value of 37.2Å,
41.7Å and 47.3Å respectively. These FRET efficiency states indicate that certainly the spread
of conformation favors more open cleft in no-ligand bound condition than when bound to
AMPA. However, the smFRET measured distance 45.3 Å in AMPA bound condition and 47.3
Å in no-ligand bound condition is similar to the cleft distance 46Å of GluK2 in an antagonist
CNQX bound Cryo-EM structure (171). These data indicate that GluK2 cleft conformation
can populate from partial cleft opening to more cleft opening during AMPA bound to the
cleft. Overall, from our data we observed that there is difference in the extent of cleft closure
in GluK2 when bound to glutamate versus AMPA and majority of conformational landscape
populates towards closed cleft arrangement in presence of glutamate and partial cleft
opening when bound to AMPA.
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5.2.2.2

Changes observed at sites across GluK5 cleft

In the case of GluK5 cleft as well, we observed the spread of conformational
population towards three FRET efficiency states in all glutamate bound, AMPA bound, and
no-ligand bound condition from cumulative FRET efficiency histogram (Figure 5-2 B-D) and
concatenated smFRET efficiency traces (Figure 5-3 B). The conformational landscape of
GluK5 cleft in glutamate bound condition is populated towards FRET efficiency states 0.94,
0.85 and 0.71 corresponding to distance of 32.2 Å, 38.2 Å and 43.9 Å respectively. The primary
conformational state of GluK5 cleft when bound to glutamate is 0.85 (38.2Å) and is similar
to the distance of 41 Å across cleft of GluK5 bound to glutamate in Cryo-EM structure of
GluK2/K5 heteromer (171). Next, from our smFRET measurements in AMPA bound
condition, we observed that the GluK5 cleft occupies FRET states 0.89, 0.81 and 0.64 having
distances of 36 Å, 40.1 Å and 46.3 Å respectively. This indicates that in AMPA bound
condition the cleft favors partial opening conformation than as compared to glutamate
bound condition. In no-ligand bound smFRET measurements, we observed the
conformational landscape of GluK5 cleft occupying FRET states 0.87, 0.76 and 0.63 with
distances value of 37.2 Å, 42.1 Å and 46.7 Å respectively. As compared to AMPA bound
measurements, the population in no-ligand bound at GluK5 subunits favors low FRET
states. Similar to GluK2 cleft, the conformational population of GluK5 cleft in AMPA bound
state also partly occupy low FRET state 0.64 which is equivalent to low FRET state observed
primarily in apo state 0.63. These distances are similar to the distance of 47 Å calculated
across GluK5 subunit in an antagonist bound Cryo-EM structure of GluK2/K5. These data
suggests that cleft conformation populates towards more cleft closing states in glutamate
82

bound condition. In AMPA bound condition, majority of the cleft conformation is observed
to favor partial cleft closure and sometimes can also occupy open cleft conformation which
is the primary conformational state observed in no-ligand bound condition.

5.2.3

Changes at the GluK2 and GluK5 cleft as seen in MD simulations

To complement the conformational changes induced at the ABD cleft observed
during smFRET and to investigate the molecular mechanism underlying difference in the
cleft closing trend at GluK2 and GluK5 subunits when bound to different agonists, we
simulated isolated ABD dimer consisting of one GluK2 and one GluK5 subunits. For the
starting structures, we prepared three homology models of GluK2/GluK5 isolated ABD
dimers bound to glutamate, bound to AMPA and apo by taking crystal structures of
homomeric GluK2 and GluA2 dimers as templates (details given in method section). Then,
we ran MD simulations for 200ns run time at glutamate bound, AMPA bound, and noligand bound conditions. To understand the change in the extent of cleft opening in ABD,
we analyzed data from the last 80 ns of the simulation trajectory by measuring the distance
across the ABD cleft between C-alpha atoms at sites 402 and 679 of GluK2 subunit and sites
395 and 673 of GluK5 subunit in the form of cleft distance histograms. The change in the
cleft distance of GluK2 and GluK5 subunits when bound to glutamate, AMPA or without
ligands is shown in Figure 5-5. At both GluK2 and GluK5 agonist binding cleft, we observed
that in presence of glutamate the cleft is tightly closed and in apo condition the cleft is open.
The difference in the extent of cleft opening when bound to glutamate and AMPA differs
by approximately 3.5-4 Å at GluK2 cleft and at GluK5 cleft by 1-2 Å suggesting both cleft
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favors partial cleft closure when bound to AMPA with slightly more opening in GluK2 cleft
than in GluK5 cleft. Our MD simulation trajectory revealed that the motion of the GluK2
cleft when bound to AMPA is more due to the loss of some interaction with sites at lower
lobe of the binding pocket. However, the GluK2 cleft explores conformational population
that favors partial open cleft states. To ensure the reproducibility of our simulation results,
we submitted another set of MD simulation on GluK2/K5 isolated dimer from the same
starting structures in glutamate bound, AMPA bound, and no-ligand bound condition for
200 ns each and analyzed the simulation trajectory (result shown in Figure 5-6). The second
set of simulation also demonstrated similar trend of partial cleft closure in both GluK2 and
GluK5 subunits in presence of AMPA and observed that difference in the extent of cleft
opening in GluK2 in presence of AMPA vs glutamate is more than in GluK5 ABD cleft.
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Figure 5-5. MD simulation on an isolated dimer of GluK2/K5.
Homology model of isolated ABD dimer of GluK2/K5 consisting of one GluK2 subunit
(shown in blue) and one GluK5 subunit (shown in green) used as a starting structure for
MD simulation. The spheres represent the sites used for calculating cleft distances for
GluK2 (magenta) and GluK5 (red) subunits. The cleft distance histograms are obtained
from simulation trajectories for GluK2 shown in left panel and GluK5 in right panel at
glutamate bound (green), AMPA bound (red) and no-ligand bound (green) conditions.
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Figure 5-6. MD simulation results from second set of simulations to test the
reproducibility of simulation results shown in Figure 5-5.

5.2.4

Comparison between cleft distances observed from MD simulations and
smFRET data

The cleft distance measurements obtained from both sets of MD simulation on an
isolated ABD dimer as well as smFRET measurements on a full-length receptor clearly
agrees well with the trend that the cleft conformation for both subunits favor closed state
in presence of glutamate, followed by partial opening of the cleft when bound to AMPA.
However, the distance between the sites across the cleft of GluK2 and GluK5 subunits varies
slightly between MD simulation and smFRET measurements. The MD simulation
measurements in this study is done on an isolated ABD dimer and hence the degree of
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freedom for ABD movement is more. Thus, we observe the wider opening of cleft
conformation especially during no-ligand bound condition. Also, the cleft histogram from
MD simulations is obtained by calculating distances between C-alpha atoms at the sites in
nanosecond time scale, whereas, for the smFRET measurements, the distance between sites
represents average fluorophore distances in millisecond to second time scale.

5.2.5

smFRET measurements to investigate the conformational changes at the
transmembrane segments of GluK2/K5

Further, to map how the difference in the degree of ABD cleft closure controls the
extent of channel activation in a heteromer GluK2/K5, we did smFRET measurements at the
transmembrane segments of both GluK2 and GluK5 subunits when bound to AMPA. We
selected sites at TMD of GluK2*-523 and GluK5*-515 (Figure 5-7 left panel) subunits which
were previously used for smFRET measurements at resting and desensitized conditions
reported in Litwin et. Al (71). We prepared smFRET measurements in the form of
concatenated FRET efficiency traces (Figure 5-8) and cumulative FRET efficiency state
histograms (Figure 5-7 right panel) to study the spread of conformational landscape of
transmembrane segments of both GluK2 and GluK5 subunits when bound to AMPA and
then compared it with the measurements done at glutamate bound desensitized conditions
previously reported. According to our previous paper Litwin et.al. we observed that during
desensitized conditions, both GluK2 and GluK5 subunits favored closed channel
conformation. The conformational change between GluK2 sites at TMD segment mainly
populated at the FRET efficiency states of 0.94 (32 Å) and 0.85 (38 Å), whereas GluK5 sites
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populated at the FRET efficiency states of 0.93 (33Å) and 0.84 (39Å) during glutamate bound
desensitized condition. In this experiment the smFRET measurements were done at GluK2
and GluK5 TMD sites in presence of AMPA and showed the partial opening of the
transmembrane segments. In presence of AMPA, the conformational landscape of GluK2
TMD sites mainly populates towards FRET efficiency states of 0.94, 0.80 and 0.61
corresponding to a distance of 32.2 Å, 40.5 Å, and 47.3 Å respectively. At GluK5 subunits,
the conformational changes at TMD sites mainly preferred FRET efficiency states of 0.94,
0.83, 0.68 corresponding to a distance of 32.2 Å, 39.15 Å and 45 Å respectively. The presence
of low FRET efficiency state in both the subunits suggested that in presence of AMPA, there
is the partial opening of both the transmembrane segments. Hence, both GluK2 and GluK5
subunits are found to be involved in the channel opening when bound to partial agonist
AMPA in a full-length GluK2/K5 heteromer leading to lower currents.
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Figure 5-7. smFRET measurements at GluK2 and GluK5 TMD in presence of AMPA.
(A, B) Left panel- Fluorophore labeling sites across the ABD cleft (red spheres) in TMD
at GluK2 subunit (blue, panel A) and GluK5 (green, panel B) of a full length GluK2/K5
(PBD 7KS0). (A, B) Right panel- Cumulative smFRET efficiency histogram data in
presence of AMPA for GluK2 TMD (panel A) and GluK5 TMD (panel B prepared by
overlaying both observed and denoised data. Gaussian fitting (black curve) is done on
observed data to represent the preferred FRET efficiency states.
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Figure 5-8. Concatenated smFRET efficiency traces for measurements across GluK2 TMD
(top panel) and GluK5 TMD (bottom panel).
The concatenated smFRET traces in blue for both GluK2 and GluK5 represent glutamate
bound desensitized condition whose smFRET efficiency histogram is shown in Figure 4-7
and Figure 4-8. For AMPA bound condition the histograms prepared from these traces
are shown in Figure 5-7.
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5.3

Discussion

The available crystal structures of homomeric kainate receptors initially suggested
that the difference in the extent of cleft closure of agonist binding domain dictates agonist
efficacy (33, 47, 62). However, this trend has not been true in case of closely related AMPA
receptors based on NMR and smFRET studies. On the other hand, the understanding of the
mechanism underlying partial agonism in a full-length GluK2/K5 kainate receptor have not
been clearly understood due to the lack of sufficient structural data. Initially through
functional studies it has been predicted that agonist AMPA selectively activates heteromer
GluK2/K5 as a partial agonist but not homomeric GluK2 (105, 117, 141). The presence of GluK5
subunit in a heteromer has been regarded as AMPA-binding subunit to activate the
heteromer. Combining MD simulations and smFRET data we were able to observe the
changes induced in the agonist binding domain of both GluK2 and GluK5 ABD when bound
to partial agonist AMPA. Further from smFRET measurements we were able to observe the
conformational changes induced at the transmembrane segments that facilitated the
channel activation in presence of AMPA.

The smFRET measurements indicated that the ABD cleft of both GluK2 and GluK5
subunits preferred three FRET efficiency states in all glutamate bound, AMPA bound, and
no-ligand bound conditions. Both subunit preferred conformations with tight cleft closure
when bound to glutamate. In the presence of AMPA, the ABD of both the subunits favored
conformations that displayed the shift of all three FRET efficiency states towards lower
value of FRET efficiency states than when bound to glutamate. This suggested that the
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binding of partial agonist AMPA to the ABD of both GluK2 and GluK5 favored
conformational population occupying partial cleft closure. Although, in both smFRET and
MD simulations we observed that the difference in the extent of cleft opening when bound
to glutamate versus AMPA on GluK2 ABD (~3-4 Å) is observed to be slightly more than that
in GluK5 subunit (~1-2 Å). It could be possible that the population favoring stable closed
cleft conformation in GluK2 when bound to AMPA is less than as compared to GluK5
subunit when bound to AMPA. Our MD simulation data have shown that AMPA loses some
interaction with sites at D2 lobe of GluK2 ABD and hence cleft closing conformation
occupied by GluK2 is relatively less stable than GluK5 cleft. This suggested that stable closed
cleft conformation in GluK5 subunits when bound to AMPA could contribute more towards
the mechanism underlying partial agonism in a heteromer.

Previous functional study has shown that the presence of asparagine at position 721
has impacted the binding of AMPA at GluK2 subunit for inducing response in homomer
(172, 173). The mutation of asparagine to serine at this site was able to induce current in
GluK2 and was identified as the key residue for activating the receptor. However, in another
study a chimeric GluK2 subunit entailing GluK5 transmembrane segment was used to
express a heteromer with GluK5 subunit (174). This heteromer with chimeric GluK2 subunit
was able to induce current in presence of glutamate and kainate as similar to its wildtype.
However, in presence of AMPA, this heteromer was unable to induce any response. Thus, it
is not solely the residue at position 721 that influences binding mechanism in GluK2 subunit
(174). It is possible that the presence of both GluK2 and GluK5 subunits work in concreted
manner to favor conformational stability for channel activation. At TMD, our smFRET
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measurements have shown both GluK2 and GluK5 undergo conformational rearrangement
to favor partial channel activation when bound to AMPA leading to lower currents. Hence,
from this study it is evident that the mechanism of partial agonism in heteromer in presence
of AMPA is not solely based on GluK5 subunit but both GluK2 and GluK5 subunits
contributing to the channel activation
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GLUN1/N2A NMDA RECEPTORS

6.1

The mechanism of negative cooperativity between the glutamate- and glycinebinding domains in NMDA receptors

Parts of this chapter are taken with permission from the research article “Durham, R.
J., Paudyal, N., Carrillo, E., Bhatia, N. K., Maclean, D. M., Berka, V., Dolino, D. M.,
Gorfe, A. A., & Jayaraman, V. (2020). Conformational spread and dynamics in
allostery of NMDA receptors. Proceedings of the National Academy of Sciences of
the United States of America, 117(7), 3839–3847”. This is a collaboration work done in
which I designed and performed the MD simulations to complement experimental data to
gain insight into the mechanism underlying negative cooperativity. The electrophysiology
work described here was done by Elisa Carrillo and David Maclean, smFRET work discussed
here was done by Ryan Durham and is included in this chapter to contextualize the MD
simulation work.
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NMDA receptors are obligate heteromers containing a glycine binding (GluN1) and
glutamate binding (GLuN2) subunit (4). Initially, the role of glycine was assumed only to
potentiate glutamate-mediated currents of NMDA receptors (12). However, it was later
confirmed

that

glycine

is

required

for

activating

the

channel

(175).

Rapid

electrophysiological measurements have established that the dissociation of one agonist
(glycine or glutamate) is faster in the presence of the second agonist (glutamate or glycine)
then in the absence (38). For these investigations, the agonist is applied for short burst to
activate the channel and the decay of currents measured upon removal of agonists to
measure the “off” rates (Figure 6-1).

These experiments are performed with the agonist in the presence and absence of
the second agonist during dissociation, thus allowing us to determine the effect of second
agonist on the dissociation rate of the first. While negative cooperativity had been
established between glycine and glutamate, the structural investigations underlying this
negative cooperativity was however not known. To investigate the mechanism of underlying
negative

cooperativity

we

investigated

the

conformational

landscape

and

dynamics/transitions across the landscape using a combination of smFRET and MD
simulations.
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Figure 6-1. Responses from outside-out patches expressing GluN1/N2A subunits.
(A) Patch was equilibrated in glycine (100 µM) and jumped into glycine plus glutamate
(1 mM) for 4 ms followed by glutamate and the low-affinity GluN1 competitive antagonist
MeICA (10 mM) to measure receptor deactivation time course upon glycine removal in
the presence of glutamate. (B) Patches were equilibrated with glycine before jumps of
variable time into control solution with MeICA to allow for glycine dissociation followed
by test pulses with glutamate. (C) Summary across 5 to 7 patches from experiments in A
and B. (D–F) Complementary experiments with the roles of glycine and glutamate
reversed to measure receptor deactivation upon glutamate removal in the presence and
absence of glycine.
Permission to use this image has been obtained from Elisa Carrillo (who performed
electrophysiology experiments and created this image) and Vasanthi Jayaraman
(corresponding author).
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Figure 6-2. Fluorophore labeling sites in GluN1/N2A for smFRET experiments.
The sites chosen to introduce cysteine mutation for fluorophore labeling is shown as red
spheres at positions Ser-507 and Thr-701 of GluN1 subunit (green) in the left panel and at
positions Gln-503 and Met-701 of GluN2 subunits (blue) in the right panel. The structure
is obtained from PBD 6MMG

The smFRET measurements were performed to study the distance across ABD by
introducing cysteines at positions Ser-507 and Thr-701 in the GluN1 glycine binding domain
and Gln-503 and Met-701 in GluN2 glutamate binding domain (Figure 6-2). These
measurements were done in the absence of agonists, presence of single agonist (glycine or
glutamate) and in the presence of both agonists. The smFRET histograms show the
population distribution for the smFRET efficiencies, from which we can determine the
fractional occupancy of the various distances that the ABD cleft occupies. These histograms
show that the ABD when bound to agonist GLuN1 when bound to glycine and GluN2 bound
to glutamate favors the high FRET/shorter distance closed cleft state when compared to the
same distances in the no agonist bound state. This is what is expected based on the end
state structures of the NMDA receptors. What was surprising is that the first ABD showed
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a wide range of FRET efficiencies with lower FRET/longer distances across the cleft when
agonist was bound to the second agonist site. That is glycine cleft explored more open cleft
states when glutamate was bound to GluN2 and vice versa. Additionally, the number of
transitions across the states was also increased at the first site when the second agonist was
bound. These studies suggested that agonist binding to one subunit altered the dynamics
and conformational landscape of the second agonist site. Such increase in dynamics and
conformations favoring an open cleft is expected to increase dissociation and these states
favor unliganded conformations.

While the smFRET investigations showed the underlying conformational
fluctuations that could be related to negative cooperativity what was missing was the
mechanism and pathway that caused such changes. In order to determine this, I used MD
simulations of the extracellular portions of one glycine-binding GluN1 and one glutamatebinding GluN2 subunit. Specifically, The GluN1/GluN2 ABDs have two major interfaces,
which are shown in Figure 6-3 IA (interface I) and Figure 6-3 IIA (interface II). To determine
the role of specific interfaces in the changes in the cleft of the individual domains and their
possible role in negative cooperativity, we performed MD simulations using minimal
constructs that maintained the interfaces of interest (Figure 6-3 IA and IIA).
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Figure 6-3. Molecular dynamics measurements of the ABD of the NMDA receptor.
(IA and IIA) The minimal constructs used for the simulations with GluN1 (tan), GluN2A
(blue), and the residues for measuring cross-cleft distances (red and blue spheres). (IB
and IIB) MD measurements of the glycine-binding GluN1 cleft. The distance between Cα
atoms of residues Ser-507 and Thr-701 was measured. (IC and IIC) MD measurements of
the glutamate-binding GluN2A cleft. The distance between Cα atoms of residues Gln-503
and Met-701 was measured.
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6.1.1

6.1.1.1

Materials and methods

Homology Modeling and MD Simulations

The homology model for the dimer of a heteromeric GluN1/GluN2A NMDA receptor
was built by using MODELLER (176) software. The template structure chosen for modeling
was the crystal structure of the Rattus norvegicus GluN1/GluN2B NMDA receptor (PDB:
4PE5 (177)). The R. norvegicus GluN2A sequence was used to prepare the homology model
and exhibited ~72% sequence identity with GluN2B. The R. norvegicus sequences can be
accessed in the UniProt Database with UniProt Id P35439 for GluN1, Q00959 for GluN2A,
and Q00960 for GluN2B. Ten model structures were prepared, and the structure with the
lowest Discrete Optimized Protein Energy (DOPE) score was utilized in the simulations. A
dimer of the extracellular domain was used as the minimal construct for the simulations in
order to preserve the extensive interactions between the two subunits at this interface. Four
independent simulations were performed: one bound to glycine, one bound to glutamate,
one bound to both, and one bound to neither. In all simulations, missing residues and
hydrogen atoms were added to the structure using the psfgen (178) module of the Visual
Molecular Dynamics software (VMD)(179) and the structure was then placed at the center
of a 113×124×136 Å box containing 18-20 charge-neutralizing sodium atoms and ~166000
TIP3P water molecules. Each system was energy-minimized using 5000 steps of conjugate
gradient energy minimization applying a restraint force of spring constant 4kcal/mol/Å2 on
the backbone atoms as well as on the sidechain heavy atoms of residues directly interacting
with the ligands. This was followed by a 5 ns equilibration simulation using a 1 fs time step
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while progressively decreasing the restraint force constant to zero. Subsequent production
runs of ~500 ns each were conducted using a time step of 2 fs under a constant number of
particles (N), pressure (P=1bar), and temperature (T=310K) ensemble, with pressure
controlled by the Nose-Hoover Langevin piston and temperature by the Langevin
thermostat. Periodic boundary conditions were used. Long-range electrostatic interactions
were calculated by the Particle Mesh Ewald (PME) method (180), with covalent bonds
involving hydrogen atoms restrained by SHAKE. Short-range non-bonded interactions were
smoothly switched off between 10 Å and 12 Å with a 14 Å cutoff used for pair list updates.
The simulations were conducted using the program NAMD 2.12 (181) and the CHARMM36
force field (182) for the NMDA receptor with the application of the cMAP dihedral
correction and the CHARMM general force field (CGENFF) (183) for the ligands. Analysis
was conducted using Tcl scripts and VMD (179).

6.1.2

Role of ABD interfaces in mediating negative cooperativity.

To examine the cleft opening/closing dynamics, the distance histograms between
the Cα atoms of T701 and S507 of the glycine-binding cleft and Q503 and M701 of the
glutamate-binding cleft (which are the sites used for smFRET measurements and are shown
in Figure 6-3 IA and IIA) were determined from the simulations after the protein was
equilibrated (Figure 6-3 I B and C and II B and C). The glycine-binding cleft for the minimal
model with interface I (Figure 6-3 IB) shows the glycine-alone bound state to be the most
closed, followed by glutamate–glycine bound, apo, and glutamate bound in that order.
Similarly for the glutamate cleft for the minimal model with interface I (Figure 6-3 IC) the
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most closed state is when glutamate is bound, followed by glutamate-glycine bound, apo,
and glycine bound in that order. The trends observed in the MD simulations, particularly
with respect to the cleft opening more in the second agonist-binding site when agonist is
bound to the first site, are similar to what is observed in the experimental smFRET
measurements,

The cleft histograms for simulations with the minimal model for interface II (Figure
6-3 II) show no changes in the degree of cleft closure at the glycine-binding domain between
the glycine-alone and glutamate–glycine bound states (Figure 6-3 IIB). The only effect seen
is a shift toward a slightly more closed state at the glycine cleft when glutamate alone is
bound relative to the apo state. At the cleft of the glutamate-binding domain (Figure 6-3
IIC) the cleft is open and similar in the case of glycine-alone and apo conditions. The only
effect seen is again in the glutamate-alone bound state, which shows a slight opening of the
glutamate-bound cleft relative to the glutamate–glycine bound state. However, the lack of
no other changes suggests that the more open cleft states relating to the cooperativity
observed in the smFRET data are mediated by interface I.

6.1.3

Discussion:

Our data show that at interface II representing dimer interface, the binding of
glutamate alone causes the glycine cleft to adopt a more closed conformation relative to no
ligand being present at both domains, which would suggest a slower dissociation of glycine
in the presence of glutamate and is more consistent with positive cooperativity and not
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negative cooperativity, counter to observations using electrophysiology and spectroscopy.
MD simulations on interface I (the interdimer interface between the ABD of GluN1 and the
ATD and ABD of GluN2A), on the other hand, show trends similar to what is observed in
the smFRET measurements underlying negative cooperativity.

103

6.2

Structural investigation to understand the role of mutation in NMDA
receptors influencing its functional properties

Parts of this chapter is taken with permission from the research article “Zhang, J., Tang,
W., Bhatia, N. K., Xu, Y., Paudyal, N., Liu, D., Kim, S., Song, R., XiangWei, W.,
Shaulsky, G., Myers, S. J., Dobyns, W., Jayaraman, V., Traynelis, S. F., Yuan, H., &
Bozarth, X. (2021). A de novo GRIN1 Variant Associated With Myoclonus and
Developmental Delay: From Molecular Mechanism to Rescue
Pharmacology. Frontiers in genetics, 12, 694312” This is a collaborative work done with
the team of Emory University. My contribution to this article involves structural
investigation by performing MD simulation to elucidate the change in functional property of
the receptor due to the mutation found in human NMDA receptor.
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The role of NMDA receptor dysfunctions has been implicated in wide range of
neurological conditions such as epilepsy, schizophrenia, Alzheimer’s, Parkinson’s,
Huntington’s diseases, neuro-developmental and cognitive disorders (4, 184, 185). A novel
point mutation at site 532 where proline is mutated to histidine at GluN1 subunit of NMDA
receptor was identified in a female patient displaying clinical phenotypes such as
developmental delay and disorders, hypoplasia and stimulus induced myoclonus. The
structural and sequence analysis suggested that proline at 532 was conserved at GluN1
subunit of all vertebrates and is located at the glycine binding domain. The team from
Emory University did pharmacological and biophysical analysis of this novel mutation to
understand its effect in receptor function. A significant decrease in the glutamate potency
in GluN1(P532H)/N2A was observed relative to the affinity in wild type GluN1/N2A. While
no significant change was observed in glycine potency. This was interesting as the mutation
is in GluN1 subunit, but the effect observed is in the function at GluN2 subunit. To
understand the structural mechanism underlying the alterations in receptor function, we
performed MD simulations.

6.2.1

Methods: MD simulation

The dimer structure of GluN1/GluN2A bound to glycine and glutamate (PBD ID
5H8Q) was taken from the Protein Data Bank for MD simulation (Figure 6-4A) (186). Two
simulation systems (wild-type and P532H variant) were prepared. The PSFGEN module of
the Visual Molecular Dynamics Simulation software (VMD) was used for building missing
residues and hydrogen atoms to the protein structure followed by protein solvation and
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ionization (178, 179). First, the protein was placed in the water box of size 97 × 90 × 105 Å,
with around 24,372 TIP3P water molecules and six chloride ions for charge neutralization
(178, 179). Total atoms in the simulation box ranged from 82,006 to 82,009. Each system was
subjected to conjugate gradient energy minimization for 5,000 steps by applying restraint
force of spring constant 4 kcal/mol/Å2 on the heavy atoms of protein and on the residues
interacting with the ligands glutamate and glycine. The system was then equilibrated for 5
ns using 1 fs time step and gradually the restraint force constant was decreased to zero.
Following system equilibration, 300 ns production was performed using 2 fs time step under
constant NTP ensemble. NTP ensemble refers to constant number of particles (N), constant
pressure of 1 bar controlled by Nose-Hoover Langevin piston and constant temperature at
310 K controlled by the Langevin thermostat. Particle mesh Ewald (PME) (187) method was
applied for calculating long-range electrostatic interactions and SHAKE restraint was used
on covalent bonds involving hydrogen atoms. Smooth switching of small range nonbonded
interaction was done between 10 and 12 Å with pair list cut-off updates on 14 Å. NAMD 2.12
(181) program was used for performing the simulation. CHARMM36 force field (182), with
cMAP dihedral correction was used for the protein. The CHARMM general force field
(CGENFF) was used for ligands (183). Simulations were submitted at Stampede2 cluster of
Texas Advancing Computing Center (TACC). MD trajectories were analyzed using TCL
scripts, VMD software and python Matplotlib (188).
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6.2.2

Results:

Snap shots of the wild type and mutant protein structure in the MD simulation
trajectories are shown in Figure 6-4B. The structures show that the histidine in the mutant
protein at site 532 in GluN1 is within 2.6 Å of the hydroxyl group of threonine 748 on the
lower lobe of GluN2A. Consistent with the interaction across the dimer there is a motion of
the lower lobe of GluN2A ABD towards the GluN1 ABD. This motion leads to an opening of
GluN2 ABD cleft as seen in the distance between the Ca atoms of sites Q503 and M701
(Figure 6-4C). No significant changes are observed in the glycine binding cleft between wild
type and GluN1-P532H mutant, as seen in the Ca atom distance between sites Ser507 and
Thr701 (Figure 6-4D). The opening in the glutamate ABD cleft and no change in glycine
agonist binding cleft is consistent with the functional measurements that show reduced
glutamate potency but only slight changes in the glycine potency between the mutant and
wild type GluN1/GluN2A receptors. The MD simulations were hence able to show the
structural pathway underlying the functional changes in this mutant.
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Figure 6-4. Effects of GluN1-P532H variant on ABD cleft distance.
A) ABD dimer, GluN1 (green) and GluN2A (rose), used for MD simulation showing sites
for measuring distances. B) Structures from MD trajectory taken from 150 to 300 ns of
simulations for wild type (green) and P532H mutation (blue). Each frame in the figure
represents the conformation of every 7.5ns simulation time, H532 and T748 are also
shown in the structure. C) Histogram of distance measurement between the Ca atoms of
sites C) S507 and T701 in GluN1 and D) Q503 and M701 in GluN2A as seen in the MD
simulation.
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CONCLUSIONS AND FUTURE DIRECTIONS

7.1

Conclusions

The progress in identifying the role of iGluRs in mammalian brain has significantly
advanced in terms of pharmacological, biophysical, and functional aspects. In the recent
years, the growth of Cryo-EM, and X-Ray crystallography has been able to solve end state
structures in facilitating the structural topology of iGluRs. The challenge underlies in
understanding the structural dynamics of these large multidomain proteins that participate
in its complex channel gating mechanism. Using cutting edge technology such as smFRET
and MD simulations, we have investigated the detailed structural mechanism of GluK2/K5
kainate receptors and GluN1/N2A NMDA receptors in understanding their unique
functional properties.

Our investigations on the heteromeric kainate receptors GluK2/K5 has been one of
the first comprehensive structural study done on a full-length receptor. For the first time
we were able to identify the structural arrangement of GluK2 and GluK5 subunits in a fulllength receptor utilizing smFRET. We were also able to identify the conformational
landscape of GluK2/K5 in functionally non-conducting yet structurally different resting and
desensitized state. We demonstrated for the first time that dimer decoupling initiates
during receptor desensitization in GluK2/K5. The comparative analysis of the extent of
dimer decoupling observed from our smFRET measurements on GluK2/K5 with previously
done smFRET measurements on homomeric GluK2 were able to explain the cause of
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functional difference between two kainate receptor subtypes. Recently on March 2021, two
full-length Cryo-EM structures for GluK2/K5 (without C-term) bound to glutamate and
antagonist CNQX were available. The subunit arrangement and conformation identified
through our smFRET measurements in resting and desensitized conditions agrees well with
Cryo-EM structures available. This indicates the robustness of smFRET technique in
investigating the subunit arrangement and conformational changes induced in a receptor
during gating mechanism. The effect of partial agonist in heteromeric kainate receptor was
previously understood only through functional studies. In addition, the understanding of
structural mechanism of partial agonism in homomeric subtypes of kainate receptors were
limited to the available end state Cryo-EM and X-Ray structures bound to different agonists.
Using MD simulation and smFRET, we were able to demonstrate the mechanism of
conformational changes induced on GluK2 and GluK5 subunits when binding to glutamate
and AMPA and how each subunit binding to AMPA translate to the extent of channel
activation leading to lower currents. This is one of the first comprehensive structural
investigations done on a full-length heteromeric kainate receptor to understand the
mechanism underlying partial agonism.

By means of MD simulation in GluN1/N2A NMDA receptor, we were able to confirm
the role of specific interface participating in negative-cooperativity mechanism which is in
good agreement with the trend observed in full-length NMDA receptor using smFRET
studies as well as functional studies previously done in our lab. Through our MD simulation
investigations, we were also able to observe the possibility of positive cooperative
mechanism between glutamate and glycine mediated through other interface suggesting
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the effect of negative cooperativity more dominance over positive cooperativity in a fulllength receptor. These findings would not have been feasible through any other techniques.

To understand the role of possible molecular interactions and conformational
changes in mutated protein is not easily accessible through any experimental techniques
and hence in silico techniques come into play. Using MD simulation, we were able identify
the possible molecular interaction altering the structural mechanism and producing unique
functional property in the mutant than as compared to its wild type in human NMDA
receptor. The conformational changes observed on isolated ABD of NMDA mutant vs wild
type during MD simulation has also been confirmed by smFRET studies on a full-length
receptor.

In conclusion, the work I have presented in this dissertation have aided the better
understanding of structural mode of action in iGluRs (GluN1/N2A NMDA receptor and
heteromeric GluK2/K5 kainate receptor) by understanding the protein dynamics and
conformational changes induced on the receptors under different conditions to explain its
underlying functional mechanism. Doing so, we are able to facilitate structural basis in
understanding complex gating mechanism in iGluRs and provide a platform in developing
subunit specific or conformation specific therapeutic drugs more accurately.
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7.2

Future directions

The combined use of MD simulation and smFRET method in understanding the
conformational changes induced in iGluRs have provided in-depth knowledge of protein
dynamics and pathway leading to unique functional property in a receptor. Yet there are
still many challenges that remained to be addressed due to the diversity in iGluRs,
complexities that are involved during channel gating and technical limitations.

7.2.1

Non-desensitizing DtoK mutation

The extent of channel opening in kainate receptors during receptor activation has
not been significantly understood as compared to AMPA receptors. Previous studies have
shown that aspartate 776 residing at the apex of the ABD closer to the dimer interface in
homomeric GluK2 when mutated to lysine, changes the receptor to non-desensitizing state.
The site homologous to Gluk2 D776 at GluK5 subunit is D760 (Figure 7-1A). Potentially this
mutant could behave as a non-desensitized mutant in GluK2/K5 and allow us to understand
the full extent of channel opening during receptor activation.
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Figure 7-1. DtoK mutation in GluK2/K5 and comparative smFRET measurements at TMD
region.
A) Sequence alignment of GluK2 and GluK5 showing the location of aspartate site of
GluK2 at 776 and GluK5 at site 760 (top) and top-down view of the structure of ABD
showing the position of D776 at GluK2 (blue) and D760 at GluK5 (green) subunits in
GluK2/K5 receptor (structure taken from PDB 7KS0). The sites are represented as red
spheres. B-C) Comparative smFRET measurements at TMD of GluK2 (B) and GluK5 (C)
in glutamate bound desensitized state (blue), AMPA (red) and D-K mutant (purple)
showing the extent of channel opening in GluK2/K5 more in the mutant.
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I performed smFRET measurements at the transmembrane segments by mutating
GluK2 site at 776 site and GluK5 site at 760 from aspartate to lysine to understand the extent
of channel opening in presence of glutamate. Then we compared our smFRET data on TMD
of GluK2 and GluK5subunits in glutamate bound and AMPA bound conditions. We were
able to see that D-K mutant has larger extent of channel opening than as compared to
AMPA bound (Figure 7-1B). The functionality of D-K mutant in GluK2/K5 is required to be
verified by using electrophysiological studies yet. Once verified, this measurement can be
used as a starting point in understanding the extent of channel opening on GluK2/K5 during
normal channel activation. We can then understand how there is the difference in the
extent of channel activation in GluK2/K5 when bound to different agonists and how the
presence of different external ions such as Na+, Li+, Cs+ modulates the receptor function of
GluK2/K5.

7.2.2

Conformational changes induced on GluK2/K5 in presence of NETO proteins

Neuropilin and Tolloid like (NETO) protein regarded as the auxiliary proteins of
kainate receptors are mainly known to mediate trafficking and channel gating of kainate
receptors. In presence of NETO proteins kainate receptors have shown to significantly
increase its functional activity by delaying the onset of receptor deactivation and
desensitization. The understanding of the conformational changes induced on kainate
receptors in presence of NETO proteins causing this functional difference as compared to
its wild type has been largely limited. Using smFRET we can understand the conformational
changes induced on GluK2/K5 in presence of NETO protein and further we can compare its
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conformational changes with the smFRET measurements for GluK2/K5 included in this
dissertation. This will allow us to map the difference in the structure-function relation of
GluK2/K5 in presence and absence of NETO protein.

Figure 7-2. Homology model of NETO protein consisting of CUB (a
complement of C1r/C1s, Uegf, BMP1) domains 1 and 2, LDL (low density
lipoprotein) region and transmembrane domain.

In addition, the interaction mechanism of kainate receptor and NETO protein has
not been well understood due to the lack of structural information for NETO proteins.
Using template-based and ab-initio protein modeling tools, I have prepared the protein
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model for NETO protein (Figure 7-2). This structure of NETO protein together with the
GluK2/K5 structure can be subjected to computational tools that provide platform for
understanding the mechanism of protein-protein interaction. Doing so, we will be able to
gain information on potential sites at the ABD and TMD of kainate receptors or domains
on NETO proteins that involve in interaction. These sites can be of potential interest in
performing smFRET experiments to triangulate the distances between NETO and GluK2/K5
to understand its interaction mechanism.

7.2.3

Steered MD simulations on iGluR family

iGluR family is a large multidomain membrane protein. Understanding the
atomistic insight of the conformational change in a membrane bound full-length receptor
of iGluR family using all atom MD simulation is computationally expensive due to the large
system size (Figure 7-3) and requires tremendous resources. One way with which this can
be addressed is by utilizing steered MD simulation (SMD) technique. SMD is generally
utilized on a biomolecule system by applying time dependent external forces to allow
system to explore conformation between initial and final desired conformation within
certain simulation time. The use of SMD has been established in providing qualitative
information of biological processes such as ligand binding and dissociation mechanism in
protein and conformational transition in biomolecules between states. The information of
conformational states obtained from smFRET measurements can be applied as a
conformational constraint on the membrane bound full-length receptor for SMD. This will
enable us to attain atomistic level insight of the system evolving from the initial state to
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desired conformational state thus gaining an understanding of the structural pathway the
receptor participates under normal physiological conditions with reasonable computational
expense.

Figure 7-3. Membrane (POPC) bound structure of GluK2/K5
The structure is obtained by using PDB ID 7KS0 and CHARMM-GUI web server
(189, 190). (Note: The total system size obtained for MD simulation after
introducing system in a simulation box included ~630K atoms)
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7.3

Final thoughts

The study of structure-function properties of iGluR channels are of tremendous
importance. The basic understanding of structural mechanism leading to its functional
behavior will help us advance towards the further understanding of how these receptors
participate in several neurological processes and in pathological conditions. The work
included in this dissertation has initiated in the understanding of structural mode of action
in GluK2/K5 kainate receptor and GluN1/N2A NDMA receptors to address its underlying
functional behavior. With the use of computational simulations such as steered MD
simulations and advanced smFRET technique such as multicolored smFRET, the
understanding of structure-function relation of iGluRs will evolve with greater details and
more accurate to the normal physiological conditions.
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APPENDICES

8.1

Methods for Chapter 4

This chapter is taken with permission from the research article “Litwin DB, Paudyal N, Carrillo
E, Berka V, Jayaraman V. The structural arrangement and dynamics of the heteromeric
GluK2/GluK5 kainate receptor as determined by smFRET. Biochimica Et Biophysica Acta
(BBA)-Biomembranes. 2020 Jan 1;1862(1):183001.”

8.1.1

Methods

8.1.2

Homology modeling

Six homology structures were built for heteromeric GluK2/GluK5, based on
homomeric GluK2 antagonist bound form (PDB 5KUH), GluK2 agonist-bound form
exhibiting desensitized state (PDB 5KUF), antagonist bound form of AMPA receptor
(PBD:3KG2), and agonist bound forms of AMPA receptor (PDB: 5WEO, 5VHZ, 4U4F). For
5VHZ, 4U4F, the agonists were also replaced by glutamate. The homology structures were
built using MODELLER software (176).

8.1.3

Generation of FRET constructs

The R. norvegicus GluK2 construct used previously in Cryo-EM (21, 24) and smFRET
(70) experiments was used and retained the native glutamine at site 590. The GluK2 coding
sequence was PCR amplified and inserted into pcDNA3.1. The background GluK2 FRET
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construct was created by mutating the non-disulfide bonded cysteines C91, C199 and C432
to serines. From this background three constructs were created. One with S266 mutated to
cysteine, one with A479 mutated to cysteine, and one with S523 mutated to cysteine.

The R. norvegicus construct containing GluK5 was kindly provided by Geoffrey
Swanson, PhD. The GluK5 coding sequence was PCR amplified and inserted into pcDNA3.1.
The background GluK5 FRET construct was created by mutating the cysteines C14, C88 and
C270 to serines. From this background three constructs were created. One with S265
mutated to cysteine, one with A471 mutated to cysteine, and one with S515.

8.1.4

Electrophysiology

HEK 293T cells at 30% confluency were transfected using lipofectamine 2000
(Invitrogen) with GluK2 and GluK5, co-transfected with GFP at a microgram ratio of 1:4:0.5.
Whole cell patch clamp recordings were performed 24–48 h after transfection, using fire
polished borosilicate glass (Sutter instruments) pipettes with 3–5 mΩ resistance, filled with
internal solution: 110 mM CsF, 30 mM CsCl, 4 mM NaCl, 0.5 mM CaCl2, 10 mM HEPES, and
5 mM EGTA (adjusted to pH 7.4 with CsOH). The external solutions contained 150 mM
NaCl, 2.8 mM KCl, 1 CaCl2 and 10 mM HEPES (adjusted to pH 7.4 with NaOH). The
glutamate (10 mM) was applied to cells using a stepper motor system (SF-77B; Warner
Instruments) with Triple barrel tubing. Recordings were performed using an Axopatch 200B
amplifier (Molecular Devices) at −60 mV hold potential, acquired at 10 kHz using
pCLAMP10 software (Molecular Devices) and filtered online at 5 kHz.
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8.1.5

smFRET sample preparation

HEK293T cells grown on 10 cm plates were checked for approximately 50%
confluency. The cells were then transfected with 20 μg DNA per 10 cm plate following
JetPrime protocol. DMEM media was changed after 4 h of transfection and incubated
overnight at 37 °C. The next day, cells were collected from two transfected 10 cm plates and
were washed with 3 mL of extracellular buffer (ECB). The sample was then wrapped in foil
and labeled with 400 nM of Alexa 555 maleimide (ThermoFisher), a donor fluorophore and
400 nM of Alexa 647 maleimide (ThermoFisher), an acceptor fluorophore, in 3 mL ECB at
room temperature for 1 h. The labeled cells were washed with 3 mL ECB and resuspended in
2 mL of solubilization buffer by nutating at 4 °C for 1 h. Solubilization buffer consists of
phosphate-buffered saline, 1% lauryl maltose neopentyl glycol (Anatrace), 2 mM cholesteryl
hydrogen succinate (MP Biomedicals), and ¼ protease inhibitor tablet (Pierce). The nutated
sample was then transferred to an ultracentrifuge tube and spun for 1 h at 44000 rpm at 4 °C
using a TLA 100.3 rotor for filtering insolubilized debris. The supernatant was collected to
be used as smFRET samples and was kept on ice until used.

8.1.6

smFRET slides preparation

Microscope glass slides (20 × 20 mm) were cleaned in a solution of Liquinox
phosphate-free detergent (Alconox Inc.) via bath sonication followed by washing with
solution consisting of 4.3% NH4OH and 4.3% H2O2. Slides were then washed with purified
water, dried with nitrogen gas, and placed in metal slide holder. Plasma cleaning of the
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slides was done using Harrick Plasma PDC-32G Plasma Cleaner and then the slides were
treated with Vectabond (Vector Laboratories, CA) for aminosilanization and stored under
vacuum. Clean silicone templates (Grace Bio-Labs) which were bath sonicated, and
methanol treated were dried using nitrogen flow and were placed at the center of the slides.
The slides were then treated with 50 μL of PEG solution (0.25% w/w biotinylated PEG, 25%
w/w mPEG-succinimidyl carbonate, 0.1 M NaHCO3) and incubated in a dark moist
environment overnight. On the day of the experiment, after cleaning the slides with purified
water and dried with nitrogen, slides were applied with short chain PEG solution (25 mM
short-chain 333 Da MS(PEG)4 Methyl-PEG-NHS-Ester Reagent, 0.1 M NaHCO3) and were
incubated at room temperature for 2–3 h. Then, the slides were washed with water, dried
with nitrogen and silicone templates were removed followed by applying Hybridwell
chambers and press-fit tubing connectors (Grace bio-Labs). 36 μL of streptavidin solution
(0.2 mg/mL streptavidin, 1× smFRET imaging buffer (1 mM DDM (n-dodecyl-β-Dmaltoside)), 0.2 mM CHS (cholesteryl hydrogen succinate), 1× PBS) was applied to the
chamber, incubated for 10 min and was washed with 1× PBS. The smFRET sample was then
applied to the slide according to the in situ immuno-precipitation SiMPull method (168)
and incubated at 4 °C for 20 min followed by washing of slides two times with 60 μL ROXS
(reactive oxygen species) scavenging solution (3.3% w/w glucose, 0.1 mg/mL pyranose
oxidase, 0.01 mg.mL catalase, 1 mM ascorbic acid, 1 mM methyl viologen and/or 1 mM
glutamate) (Sigma-Aldrich). Finally, the slides were ready for imaging.
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8.1.7

smFRET data collection

A PicoQuant MicroTime 200 Fluorescence Lifetime Microscope was used for
acquiring the smFRET data with pulsed interleaved excitation (PIE) set at 80 MHz. The
fluorophores were excited by using 532 nm (LDH-D-TA-530; Picoquant) and 637 nm (LDHD-C-640; Picoquant) lasers simultaneously. The sample slide positioned on a scanning x-yz piezo stage (P-733.2CD; Physik Instrumente) was observed through an oil immersed 100×
objective lens (100× 1.4 NA; Olympus). Two SPAD photodiodes (SPCM CD3516H; Excelitas
technologies) collected photons emitted from the sample passing through objective to the
emission filters 550 nm (FF01–582/64; AHF/Semrock) and 650 nm (2XH690/70; AHF) to the
photodiodes. These emission filters help us to visualize the donor and the acceptor channel.

8.1.8

smFRET data analysis

Molecules exhibiting a single donor and single acceptor photobleaching step with
anticorrelation upon acceptor bleaching were used for analysis. Intensities for the donor
and acceptor were then used for the calculation of FRET efficiencies. MATLAB
(MathWorks) was used for denoising donor and acceptor traces using wavelet based
denoising. Origin (OriginLab Corp) was used for creating smFRET histograms and traces.
The number of states which best describes the efficiencies obtained for each dataset was
determined using Step Transition and State Identification (STaSI) (79) and Gaussian fitting.
The total number of molecules used for the analysis of each condition are, 28 molecules for

123

GluK2*-266 - GluK2*-266, 26–28 molecules for GluK2*-479 - GluK5*-471, and 27–31
molecules for GluK2*-523 - GluK2*-523 and GluK5*-515 -GluK5*-515.

8.2

Methods for Chapter 5

(Mechanism underlying partial agonism in

heteromeric GluK2/K5)

8.2.1

MD Simulation

The starting structure of the ABD dimer of GluK2/K5 for MD simulation was built
by using MODELLER software (176). The crystal structure of PDB ID 3G3F, 1LB8 and 3S2V
was used for modeling GluK2/K5 dimer bound to glutamate, ampa and apo condition
respectively. The sequence for homology modeling was taken from the Uniprot database of
ID P39087 for GluK2 and Q63273 for GluK5. The structures for simulations were selected
based on the lowest obtained Discrete Optimized Protein Energy (DOPE) score (191) out of
10 models prepared for each condition. Six independent simulations were performed with
two sets of simulation for each glutamate bound, AMPA bound, and no-ligand bound
respectively. The psfgen module of Visual Molecular Dynamics software was used to add
missing residues and hydrogen atoms to the structures (178, 179). For glutamate bound
structure, the protein was placed at the center by using the box size of 83 × 90 × 87 Å
containing 51269 TIP3P water molecules and two charge neutralizing sodium ions. The
simulation box contained total of 59486 atoms. For AMPA bound structure the box size was
93 × 103 × 79 Å containing 60725 TIP3P water molecules, one charge neutralizing chloride
ion and 69133 total atoms. Whereas for apo structure the box size was 91 × 86 × 90 Å
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containing 56408 TIP3P water molecules, one charge neutralizing chloride ion and 64594
total atoms.

For equilibration, each system was energy minimized by applying 5000 steps of
conjugate gradient energy. At the backbone atoms and residues directly interacting to the
ligands, a restraint force of spring constant 4 kcal/mol/Å2 was applied. A 5ns of simulation
equilibration was achieved using a 1fs time step and the restraint force constant
progressively reduced to zero. The production runs of 200ns were achieved using a time
step of 2 fs under NTP ensemble condition consisting of constant number of particles (N),
temperature (T=310K) and pressure (P=1bar). Nose-Hoover Langevin piston was used for
controlling the pressure whereas, Langevin thermostat for controlling temperature. The
boundary conditions applied are periodic in nature. Particle Mesh Ewald method (180) was
used for calculating long-range electrostatic interactions where covalent bonds that
involved hydrogen atoms were restrained by SHAKE algorithm. For the short range
nonbonded interactions, the smooth switching was done between 10 Å and 12 Å with a 14-Å
cutoff for pairlist distances. NAMD 2.12/2.13 (181) was used for conducting MD simulation
with CHARMM36 force field (182) and cMAP dihedral correction applied for the proteins.
Ligands were parameterized using CHARMM general force field (CGENFF) (183). The
analysis for MD trajectory results were obtained by using VMD (179), Matplotlib (188) and
scripts written in TCL and python.
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8.2.2

DNA constructs for smFRET:

The construct of R. norvegicus GluK2EM kindly provided by Dr. Mark Mayer and
GluK5 kindly provided by Dr. Geoffrey Swanson used previously in smFRET experiments
(70, 71) were used. The GluK2EM construct retained the native glutamine at site 590. For
smFRET measurements, the GluK2 and GluK5 constructs were made cysless by mutating
extracellular cysteines lacking non-disulfide bonds changed to serines. For cysless
constructs of GluK2* the cysteine sites C91, C199, and C432 were mutated to serines.
Whereas the cysless constructs of GluK5* were made by mutating cysteines to serines at
sites C14, C88 and C270. On the background of GluK2* and GluK5* constructs, further
mutations were made using standard PCR-based mutagenesis to make two more constructs.
For GluK2*-cleft construct was made with L402 (RSLIVT) and S679 (FMSSR) sites both
mutated to cysteine and GluK2*-TMD construct with site S523 (GVFSFL) mutated to
cysteine. Whereas, for GluK5*-cleft construct was made with L395 (NKTLVV) and 673
(MQSKQ) sites both mutated to cysteine and GluK5*-TMD construct with site S515
(GYFSFL) mutated to cysteine. The residue numbering done for smFRET constructs are the
same as in Litwin et. Al (71). All the constructs were PCR modified and inserted to
pcDNA3.1. The mutations were verified with Genewiz sanger sequencing.

8.2.3

Electrophysiology

HEK 293 T cells were transfected using lipofectamine 2000 [(GluK2*-Cleft, GluK5*),
(GluK2*-TMD, GluK5*), (GluK2*, GluK5*-Cleft), (GluK2*, GluK5*-TMD)] and co-
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transfected with GFP at a microgram ratio of 3:1:1. Whole cell patch clamp recordings were
performed 24–48 h after transfection, using fire-polished borosilicate glass (Sutter
instruments) pipettes with 3–5 mΩ resistance, filled with internal solution: 110 mM CsF, 30
mM CsCl, 4 mM NaCl, 0.5 mM CaCl2, 10 mM HEPES, and 5 mM EGTA (adjusted to pH 7.4
with CsOH). The extracellular solution consisted of 150 mM NaCl, 2.8 mM KCl, 1.8 mM
CaCl2, 1.0 mM MgCl2, and 10 mM HEPES, adjusted to pH 7.4 with NaOH. External solutions
were locally applied to lifted cells using a SF-77B perfusion fast-step (Warner Instruments),
in the presence or absence of 1 mM ligands (glutamate or AMPA). Recordings were
performed using an Axopatch 200B amplifier (Molecular Devices) at −60 mV hold potential,
acquired at 10 kHz using pCLAMP10 software (Molecular Devices), and filtered online at 5
kHz

8.2.4

8.2.4.1

smFRET methods

smFRET sample preparation:

HEK 293T cells grown on 10cm plates at 37C in DMEM media with 5% CO2 were
first checked for ~50% confluency. Using JetPrime protocol these cells were then transfected
with 20μg of DNA per 10cm plate in a 1:3 ratio of GluK2 and GluK5 DNA respectively. After
4 hrs of transfection DMEM media was changed and the cells were incubated at 37
overnight. Two plates were transfected for each experiment. The next day, transfected cells
were harvested and washed in 3mL of extracellular buffer (ECB). In a 3mL ECB buffer, the
sample was then labeled with donor fluorophore 400 nM of Alexa 555 maleimide
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(ThermoFisher) and acceptor fluorophore 400 nM of Alexa 647 maleimide (ThermoFisher)
for 1 hr at room temperature. The sample was covered with foil during labeling to prevent
photobleaching. After labeling, the sample was again washed with 3 mL ECB solution and
resuspended in 2 mL of solubilization buffer [phosphate-buffered saline, 1% lauryl maltose
neopentyl glycol (Anatrace), 2 mM cholesteryl hydrogen succinate (MP Biomedicals), and
¼ protease inhibitor tablet (Pierce)]. The sample was then nutated at 4 °C for 1 hr and later
was transferred to an ultracentrifuge tube. Using a TLA 100.3 rotor the sample was then
spun for 1 hr at 44000 rpm at 4 °C. The supernatant was collected and used as smFRET
samples. The remaining sample was kept at 4 °C until used.

8.2.4.2

smFRET slides preparation:

The silicone templates (Grace bio-labs) were cleaned using bath sonication and
stored in methanol. Microscope cover slides (20 × 20 mm) were first cleaned with 5%
Liquinox phosphate-free detergent (Alconox Inc.) solution using bath sonication and then
washed with a solution consisting of 4.3% NH4OH and 4.3% H2O2. Further, the slides were
washed with molecular biology grade water, and dried with nitrogen gas. The slides were
then placed in a metal holder and was set to plasma cleaning using Harrick Plasma PDC32G Plasma Cleaner. Then the slides were aminosilanized with Vectabond (Vector
Laboratories, CA), dried gently with nitrogen flow and stored in vacuum. The day before
the experiment, the clean silicone template stored in methanol was first dried with nitrogen
flow and was placed at the center of the clean slide. Separately 50 μL of PEG solution (0.25%
w/w biotinylated PEG, 25% w/w mPEG-succinimidyl carbonate, 0.1 M NaHCO3) was
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prepared, then was applied at the oval region of the slide made by silicone template, and
incubated overnight in the dark at room temperature. On the day of the experiment, the
slide was first cleaned with water, dried with nitrogen flow, and applied with 50 μL of shortchain PEG solution (25 mM short-chain 333 Da MS(PEG)4 Methyl-PEG-NHS-Ester Reagent,
0.1 M NaHCO3). The slide was then incubated at room temperature for 2-3 hrs. Next, the
slide was cleaned with water and dried with nitrogen flow. The marking of the oval area was
done, the silicone template was removed and an adhesive Hybriwell chamber (Grace BioLab) was applied to the slide. Press-fit tubing connectors were then applied at the port of
the chamber. Streptavidin solution was separately prepared using 0.2 mg/mL streptavidin
in 1×smFRET imaging buffer [1 mM DDM (n-dodecyl-β-D-maltoside)), 0.2 mM CHS
(cholesteryl hydrogen succinate), 1× PBS] and was applied to the slide through the inlet port
until the solution was flown through the outlet port. The streptavidin treated slide was then
incubated for 10 mins and washed with 1xPBS by applying through the inlet port. The
smFRET protein sample was then applied to the slide and was incubated for 20 mins at 4°C.
During the wait time, reactive oxygen species (ROXS) scavenging solution was prepared
with 3.3% w/w glucose, 0.1 mg/mL pyranose oxidase, 0.01 mg/mL catalase, 1 mM ascorbic
acid, 1 mM methyl viologen and/or 1 mM ligand (glutamate or AMPA) and pH set to 7.5 if
needed. Finally, the slide was washed with ROXS solution through the inlet port and was
ready for imaging.
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8.2.4.3

smFRET Data Collection

A custom built PicoQuant MicroTime 200 Fluorescence Lifetime Microscope was
used for acquiring the smFRET data. Pulsed interleaved excitation (PIE) which was set at
80 MHz was used for exciting the fluorophores using 532 nm (LDH-D-TA-530; Picoquant)
and 637 nm (LDH-D-C-640; Picoquant) lasers simultaneously. The sample slide which was
placed on a scanning x-y-z piezo stage (P-733.2CD; Physik Instrumente) was observed
through a 100× objective lens (100× 1.4 NA; Olympus) immersed in an oil. From the sample
the photons were emitted to back to the objective lens and to the emission filters 550 nm
(FF01–582/64; AHF/Semrock) and 650 nm (2XH690/70; AHF) which later were detected by
two SPAD photodiodes (SPCM CD3516H; Excelitas technologies). The visualization of the
donor and the acceptor channel is possible due to emission filters.

8.2.4.4

smFRET data acquisition and analysis:

A protocol for smFRET data collection and data analysis has been included in detail
in book chapters Litwin et al. and Paudyal et al. (192, 193). For agonist bound conditions,
the total number of molecules used in the final analysis during different conditions are as
follows-

K2 Cleft
Glu bound: 52 molecules
AMPA bound: 56 molecules
APO: 55 molecules
K2 TMD
AMPA bound: 58 molecules

K5 Cleft
Glu bound: 52 molecules
AMPA bound: 52 molecules
APO: 54 molecules
K5 TMD
AMPA bound: 60 molecules
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Each molecule exhibiting single acceptor and single donor photobleaching steps
with anti-correlation upon acceptor photobleaching was collected for analysis. FRET
efficiencies were calculated using donor and acceptor intensities. The FRET efficiency
histogram was prepared by using MATLAB (MathWorks) and represent the cumulative
histogram of total molecules listed above for each condition. Denoised FRET efficiency
histogram is prepared by wavelet based denoising using MATLAB. The histograms allow us
to identify the fractional occurrence of various smFRET efficiency traces. For determining
the best FRET efficiency states for the histograms Gaussian fitting method was applied using
Origin (Origin Lab Corp). States identified using Step Transition and State Identification
(STaSI) (79) were used as guiding parameters for gaussian fitting. For smFRET concatenated
traces, Origin (Origin Lab Corp) was used for denoising of the data by 3-level wavelet
decomposition at 65% threshold level.
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